4'-substituted nucleosides and nucleotides as antiviral agents

HK40137398APending Publication Date: 2026-09-11THE SCRIPPS RES INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125032
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-28
Filing Date
2026-06-18
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present application provides nucleoside analog compounds of Formula I-V for use in the treatment of dengue (DF). The present application further provides compositions and combinations thereof and methods of treating dengue fever using the nucleoside compounds of Formula I-V and compositions and combinations thereof.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480040745.2 (22) Application Date 2024.04.29 (30) Priority Data 63 / 498,910 2023.04.28 US (85) PCT International Application Entering National Phase Date 2025.12.18 (86) PCT International Application Application Data PCT / US2024 / 026825 2024.04.29 (87) PCT International Application Publication Data WO2024 / 227159 EN 2024.10.31 (71) Applicant: Scripps Research Institute, USA (72) Inventors: Yu Chenguang, Anna Chatterjee, Laura Rivakaren C. Wolfkas W. McNamara, You Hengyao, Anil Kumar Gupta, Omar Saleh (74) Patent Agency: Zhongyuan Xinda Intellectual Property Agency Co., Ltd., 11219 Patent Attorneys: Liu Hui, Jin Haixia (51) Int.Cl. C07H 19 / 14 (2006.01) A61K 31 / 519 (2006.01) A61K 31 / 52 (2006.01) A61K 31 / 7064 (2006.01) C07D 473 / 34 (2006.01) C07H 19 / 052 (2006.01) C07H 19 / 12 (2006.01) A61P 31 / 14 (2006.01) (54) Invention Title: 4'-Substituted Nucleosides and Nucleotides as Antiviral Agents (57) Abstract: This application provides nucleoside analog compounds of formulas I-V for the treatment of dengue fever (DF). This application further provides compositions and combinations thereof, and methods of treating dengue fever using nucleoside compounds of formulas I-V and their compositions and combinations thereof. Claims (13 pages), Description (81 pages), Drawings (2 pages) CN 121358746 A 2026.01.16 CN 1 21 35 87 46 A 1. A compound of formula (I) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O)(C1-C6)alkylaryl (C5-C8) heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2, -P(=O)(OR1')2, -P(=O)(OR1') 1')-P(=O)(OR1')-P(=O)(OR1')2、-P(=O)(OR1')NH(C1-C6)alkyl、-P(=O)(OR1')NH(C1-C6)heteroalkyl、-P(=O)(OR1')NH(C1-C6)haloalkyl、-P(=O)(OR1')NH(C3-C7)cycloalkyl、-P(=O)(OR1')NH(C3-C7)heterocycloalkyl、-P(=O)(OR1')NH(C6-C10)aryl、-P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl、-P(=O)(OR1')NH(C5-C8)heteroaryl、-P(=O) (OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O)(NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1') NH(C3-C7) heterocyclic alkyl, -P(=O)(NHR1')NH(C6-C10) aryl, -P(=O)(NHR1')NH(C1-C6) alkyl(C6-C10) aryl, -P(=O)(NHR1')NH(C5-C8) heteroaryl, -P(=O)(NHR1')NH(C1-C6) alkyl(C5-C8) heteroaryl, -P(=O)(OR1')NH(C1-C6) alkyl-C(=O)O-(C1-C6) alkyl, -P(=O)(OR1')NH(C1-C6) heteroalkyl-C(=O)O-(C1-C6) Alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl -C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; Each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkylynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl, or -(C1-C6)alkyl(C5-C8)heteroaryl; R2a is H, halo, (C1-C6)alkyl, or -C≡CH; R2b is independently halo or OH; R3 is independently H or OH; R4 is N3, halo, -C≡N, (C1-C3)haloalkyl, or -O(C1-C6)alkyl; R5 is H, halo, -C≡N, (C1-C6)alkyl, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, N(R1')2, or -C(=O)NH2; R6 is H, halo, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)ynyl; Claims 1 / 13 page 2 CN 121358746 A R7 is H, NH2, OH, oxo, halo, N(R1')2, or -O(C1-C6)alkyl; and R8 is H or halo; The condition is that the compound of formula I is not 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; 4-amino-7-((2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxylonitrile; ((5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl- 2-Fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; ((5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; (5-(4-amino-5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; (5-(4-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4- Dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; Including enantiomers, racemic and non-racemic mixtures, and further including their pharmaceutically acceptable salts. 2. A compound of formula (II) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(= O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O)(C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')-P(=O)(OR1')2, - P(=O)(OR1')NH(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl, -P(=O)(OR1')NH(C3-C7)cycloalkyl, -P(=O)(OR1')NH(C3-C7)heterocycloalkyl, -P(=O)(OR1')NH(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O) (OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O)(NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocyclicalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl Claims 2 / 13 pages 3 CN 121358746 A alkyl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl- C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3- R2 is H, (C1-C6)alkyl, or -C≡CH; R4 is N₃, halogenated, or -O(C1-C6)alkyl; R5 is H, halogenated, -C≡N, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, N(R1')₂, or -C(=O)NH₂; R6 is H, halogenated, NH₂, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)ynyl. R7 is H, NH2, OH, halogenated, N(R1')2, or -O(C1-C6)alkyl; and R8 is H or halogenated; provided that the compound of formula II is not (2S,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3S,4R,5S)-5-(4-amino- 5-Fluoropyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R, 3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl-5-d)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate or ((((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate or ((((2R,3S,4R,5S)-5-(4-aminopyrrolo)[2,1-f][1,2,4]triazine-7-yl)-2-azido-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-D-alanine 2-ethylbutyl ester; comprising enantiomers, racemic and non-racemic mixtures, and further comprising pharmaceutically acceptable salts thereof. 3. A compound of formula (IIIa) or (IIIb) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O)(C1-C6)alkyl. (Claims 3 / 13, page 4, CN 121358746 A) aryl (C5-C8) heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2, -P(=O)(OR1')2, -P(=O)(OR1') 1')-P(=O)(OR1')-P(=O)(OR1')2、-P(=O)(OR1')NH(C1-C6)alkyl、-P(=O)(OR1')NH(C1-C6)heteroalkyl、-P(=O)(OR1')NH(C1-C6)haloalkyl、-P(=O)(OR1')NH(C3-C7)cycloalkyl、-P(=O)(OR1')NH(C3-C7)heterocycloalkyl、-P(=O)(OR1')NH(C6-C10)aryl、-P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl、-P(=O)(OR1')NH(C5-C8)heteroaryl、-P(=O) (OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O)(NHR1')NH(C1-C6)Heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocycloalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O) (OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl(C6- C10) aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, - (C2-C6)heterenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heterynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R2a is H, OH, halogenated, (C1-C6)alkyl or -C≡CH; R2b is H, OH, halogenated or (C1-C6)alkyl; R3a is H, OH, halogenated or (C1-C6)alkyl; R3b is H, OH, halogenated or (C1-C6)alkyl; R4 is N3, halo, -C≡N, (C1-C3) haloalkyl or -O(C1-C6)alkyl;R6 and R6' are each independently halogenated, NH2, NH(C1-C6)alkyl, N((C1-C6)alkyl)2, -OH, -O(C1-C6)alkyl, -oxo, or -C≡CH; and R8 is H or halogenated; provided that the compound of formula III is not (((2R,3S,4R,5R)-5-(2,6-diamino-9H-purin-9-yl)-2-(difluoromethyl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; (((2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; (2S,3S,4R,5R)-5-(2 (6-Diamino-9H-purin-9-yl)-2-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; including enantiomers, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof. 4. A compound of formula (IV) (Claims 4 / 13, page 5, CN 121358746 A) Wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(= O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O)(C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH (C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl, -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')-P(=O)(OR1')2、P(=O)(OR1')NH(C1-C6)haloalkyl、-P(=O)(OR1')NH(C3-C7)cycloalkyl、-P(=O)(OR1')NH(C3-C7)heterocycloalkyl、-P(=O)(OR1')NH(C6-C10)aryl、-P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl、-P(=O)(OR1')NH(C5-C8)heteroaryl、-P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl、-P(=O)(NHR1')NH(C1-C6)alkyl、-P(=O)(NHR1')NH(C1-C6) Heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocycloalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O) (OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl(C6- C10) aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heterenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heterynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R4 is N3, halo, or -O(C1-C6)alkyl; and R6 is H, halo, (C1-C6)alkyl, (C2-C6)alkenyl or (C2-C6)ynyl; including enantiomers, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof. 5. A compound of formula (V) (Claims 5 / 13, page 6, CN 121358746 A) Wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(= O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O)(C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH (C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')-P(=O)(OR1')2, - P(=O)(OR1')NH(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl, -P(=O)(OR1')NH(C3-C7)cycloalkyl, -P(=O)(OR1')NH(C3-C7)heterocycloalkyl, -P(=O)(OR1')NH(C6-C10) aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O)(NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1') NH(C3-C7) heterocyclic alkyl, -P(=O)(NHR1')NH(C6-C10) aryl, -P(=O)(NHR1')NH(C1-C6) alkyl(C6-C10) aryl, -P(=O)(NHR1')NH(C5-C8) heteroaryl, -P(=O)(NHR1')NH(C1-C6) alkyl(C5-C8) heteroaryl, -P(=O)(OR1')NH(C1-C6) alkyl-C(=O)O-(C1-C6) alkyl, -P(=O)(OR1')NH(C1-C6) heteroalkyl-C(=O)O-(C1-C6) Alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl, -C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl, -C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl, -C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl, -C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O) (OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3- C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl;R2 is H, halo, (C1-C6)alkyl, or -C≡CH; R4 is N3, halo, -C≡N, (C1-C3)haloalkyl, or -O(C1-C6)alkyl; R5 is H, halo, -C≡N, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, N(R1')2, or -(C(=O)NH2); R6 is H, halo, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)ynyl; R7 is H, NH2, OH, halo, N(R1')2, or -O(C1-C6)alkyl; and R8 is H or halo; It includes enantiomers, racemic and non-racemic mixtures, and further includes pharmaceutically acceptable salts thereof. Claims 6 / 13 pages 7 CN 121358746 A 6. The compound of claim 1, wherein R2b is OH or halogenated. 7. The compound of claim 3, wherein R2b is halogenated. 8. The compound of claim 7, wherein R2a is Me or halogenated. 9. The compound of any one of claims 6-8, wherein R2a is H. 10. The compound of any one of claims 6-8, wherein R2a is (C1-C6) alkyl. 11. The compound of claim 10, wherein R2a is Me. 12. The compound of any one of claims 6-8, wherein R2a is halogenated. 13. The compound of claim 12, wherein R2a is Cl. 14. The compound of any one of claims 2 or 5, wherein R2 is H. 15. The compound of any one of claims 2 or 5, wherein R2 is halogenated. 16. The compound of claim 15, wherein R2 is F. 17. The compound of any one of claims 2 or 5, wherein R2 is (C1-C6) alkyl. 18. The compound of claim 17, wherein R2 is Me. 19. The compound of any one of claims 1-2 or 5, wherein R5 is H. 20. The compound of any one of claims 1-2 or 5, wherein R5 is -CH2OH. 21. The compound of any one of claims 1-2 or 5, wherein R5 is -C(=O)NH2. 22. The compound of any one of claims 1, 6-13 or 19-21, wherein R3 is OH. 23. The compound of any one of claims 1, 6-13 or 19-21, wherein R3 is H. 24. The compound of any one of claims 1-23, wherein R4 is halogenated. 25. The compound of claim 24, wherein R4 is F. 26. The compound of claim 24, wherein R4 is Cl. 27. The compound of any one of claims 1-23, wherein R4 is N3.28. The compound of any one of claims 1-23, wherein R4 is -O(C1-C6)alkyl. 29. The compound of claim 28, wherein R4 is -OMe. 30. The compound of any one of claims 1-29, wherein R6 is H or NH2, and R6' is -NH(C1-C6)alkyl or -O(C1-C6)alkyl. 31. The compound of any one of claims 1-29, wherein R6 is halogenated. 32. The compound of claim 31, wherein R6 is F. 33. The compound of any one of claims 1-29, wherein R6 is -C≡CH. 34. The compound of any one of claims 1-33, wherein R1 is H. 35. The compound of any one of claims 1-33, wherein R1 is -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2, or -P(=O)(OR1')-P(=O)(OR1')-P(=O)(OR1')2. 36. The compound of any one of claims 1-33, wherein R1 is -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl. 37. A compound having any of the following formulas: (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; Claims 7 / 13 pages 8 CN 121358746 A (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-(hydroxymethyl)-2-methoxy-4-methyltetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3R,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-chloro-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R ,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-4-chloro-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol;(2R,3R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-azido-5-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-2-(hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol; (2R,3R) (2R,3R,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol; (2S,3S,4R,5R)-2-fluoro-5-(4-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 4-amino-7-((2R,3R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; (2S,3S,4R,5R)-5-(4-amino-5-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(6-amino-2-ethynyl-9H-purine-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5S)-5-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R) ,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(fluoromethyl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 5-fluoro-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; (2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl) Claims 8 / 13 pages 9 CN 121358746 A Tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2S,3S,4R,5R)-5-(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxylonitrile; (2S,3S,4R,5R)-5-(2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R)-5-(2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R) (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(6-(methylthio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (1S,2S,3S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-3-(hydroxymethyl)cyclopentane-1,2-diol; (2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrofuran-2-carboxylonitrile; (2S,3S,4R,5R)-5-(4-amino-5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; benzoic acid ((2S,3S,4R,5S)-5-(4-amino-5-carbamoylpyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester;(2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-carboxynitrile; 7-((2R,3R)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-carboxynitrile; (2R,3R,5R)-5-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2R,3R,5R)-5-fluoro-5-(hydroxymethyl)-2-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3-ol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-amino-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; Claims 9 / 13 pages 10 CN 121358746 A (2S,3S,4R,5R)-5-(6-amino-2-chloro-9H-purine-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 4-amino-1-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; (2S,3S,4R,5R)-2-((benzoyloxy)methyl)-5-(3,5-dioxo-4,5-dihydro-1,2,4-triazine-2) (3H)-yl)-2-fluorotetrahydrofuran-3,4-dimethyldiacetate; Isobutyric acid ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-dimethylbis(2-methylpropionate); ((S)-(((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxyTetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((R)-(((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; Benzoic acid ((2S,3S,4R,5R)-4-(benzoyloxy)-5-(4-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl ester; (2R,3R,4S,5S)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carboxylon; (2S,3S,4R,5R)-5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R (2S,3R,5R)-5-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3R,5R)-5-(4-amino-5-(benzo[d]thiazolyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,4,4-trifluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; benzoic acid ((2S,3S,4R,5R)-5-(2-amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; (2S,3R) ,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; ((R)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((S)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; (2S,3R) ,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-2,4,4-trifluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol;((((2S,3R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-2,4,4-trifluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; 2-amino-9-((2R,3R,4R,5S)-3-chloro-5-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)- Claims 10 / 13 pages 11 CN 121358746 A 1,9-dihydro-6H-purin-6-one; (2S,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol; ((((2S,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((((2S,3S,4R,5R)-5-(4-aminoimidazo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(naphthyl-1-yloxy)phosphoryl)-L-alanine neopentyl ester; (2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol); ((((2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; 2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-4-bromo-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; ((((2S,3R,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-2,4,4-trifluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; (2S,3S,4R,5R)-4-ethynyl-2-fluoro-2-(hydroxymethyl)-5-(4-(propylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; 2-amino-9-((2R,4R,5S)-3,3,5-trifluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purine-6-one; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;Hydrofuran-3,4-diol; L-valine ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; ((((2S,3S,4R,5R)-5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(naphthyloxy)phosphoryl)-L-alanine neopentyl ester; ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-2-fluoro-3,4-dihydroxy-5-(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R) (2S,3S,4R,5R)-5-(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; (2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; (2S,3S,4R,5R)-5-(4-aminoimidazo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; Claims 11 / 13 pages 12 CN 121358746 A ((2S,3S,4R,5R)-5-(4-amino-5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purine-9-yl)-4-chloro-2-fluoro-3-hydroxy-4-Methyltetrahydrofuran-2-yl)methyltetrahydrotriphosphate; and ((2S,3S,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methyltetrahydrotriphosphate. 38. The compound of claim 37, having the chemical formula (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol or ((R)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester. 39. A pharmaceutical composition comprising the compound of any one of claims 1-38, mixed with a pharmaceutically acceptable carrier, diluent, or excipient. 40. The pharmaceutical composition of claim 39, further comprising one or more therapeutic compounds or compositions. 41. The pharmaceutical composition of claim 40, wherein one or more therapeutic compounds or compositions are second antiviral compounds or compositions. 42. The pharmaceutical composition of claim 41, wherein the second antiviral compound or composition is an RdRp inhibitor. 43. The pharmaceutical composition of claim 41, wherein the second antiviral compound or composition is an RNA polymerase inhibitor. 44. A method of inhibiting RNA-dependent RNA polymerase, comprising administering to a subject in need a therapeutically effective amount of a compound as described in any one of claims 1-38 or a pharmaceutical composition as described in claims 39-43. 45. A method of preventing, improving, or treating RNA virus infection, comprising administering to a subject in need a therapeutically effective amount of a compound as described in any one of claims 1-38 or a pharmaceutical composition as described in claims 39-43. 46. ​​The method of claim 45, wherein the RNA virus infection is at least one virus selected from the group consisting of: dengue virus, South Asian respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, Zika virus, yellow fever virus, Ebola (Macona) virus, Ebola (Kikwet) virus, Bundibugyo virus, Sudan virus, Marburg virus, respiratory syncytial virus (RSV), Nipah virus, measles virus, parainfluenza virus, Middle East respiratory syndrome (MERS) virus, hepatitis C virus (HCV), West Nile virus, Lassa virus, influenza, HRV, MEV, LCMV, poliovirus, CHIKV, COXV, and Junin virus. 47. The method of claim 46, wherein the RNA virus infection is caused by dengue virus.48. The method of claim 46, wherein the RNA virus infection is caused by SARS-CoV-2 virus. 49. The method of claim 46, wherein the RNA virus infection is caused by yellow fever virus. 50. The method of claim 46, wherein the RNA virus infection is caused by Zika virus. 51. The method of any one of claims 44-50, further comprising treatment with one or more additional therapeutic compounds or compositions. 52. The method of claim 51, wherein at least one of the one or more therapeutic compounds or compositions is an effective drug for treating or improving RNA virus infection. Claims 12 / 13 pages 13 CN 121358746 A 53. The method of claim 52, wherein the drug for treating RNA virus infection is selected from remdesivir, monoprevir, or parovir. 54. Any compound, composition, or method as described herein. Claims 13 / 13 Page 14 CN 121358746 A 4'-substituted nucleosides and nucleotides as antiviral agents Cross-reference to related applications

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 498,910, filed April 28, 2023, which is hereby incorporated by reference in its entirety. Technical Field

[0002] This application provides nucleoside analog compounds of formulas I-V for the treatment of dengue fever (DF). This application further provides compositions and combinations thereof, as well as methods of treating dengue fever using nucleoside compounds of formulas I-V and their compositions and combinations thereof. Background Art

[0003] Dengue fever is an acute febrile illness caused by one of four closely related viral serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Dengue fever is classified according to its clinical characteristics into typical dengue fever or more severe forms (i.e., dengue hemorrhagic fever syndrome, DHF) and dengue shock syndrome (DSS). Recovery from infection with one serotype provides lifelong immunity to that specific serotype, but offers only temporary and limited protection against any other serotype. Dengue is a member of the Flaviviridae family, which consists of enveloped, positive-sense RNA viruses that also include West Nile virus (WNV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), and tick-borne encephalitis virus (TBEV) in humans. Dengue is primarily transmitted through the bite of infected Aedes aegypti mosquitoes, which are currently found in tropical and subtropical regions worldwide.

[0004] Annual regional dengue epidemics impose significant morbidity and mortality rates, social disruption, and a heavy economic burden on affected communities in terms of hospitalization and mosquito control. Dengue is considered by the World Health Organization (WHO) to be one of the most serious diseases.Dengue is a viral disease transmitted by arthropods, with an estimated 50 million cases of dengue infection worldwide each year, including 500,000 cases of dengue fever (DHF) and 24,000 deaths. The WHO estimates that 40 percent of the world’s population (2.5 billion people) is at risk of dengue fever (DF), DHF, and DSS. Dengue virus is also a NIAID Category A pathogen and poses a significant threat to U.S. military personnel stationed overseas from a biodefense perspective. Dengue fever is an emerging threat to North America, with a dramatic increase in severe cases over the past 25 years, including large-scale epidemics in Cuba and Venezuela and outbreaks in Texas and Hawaii.

[0005] Failure to control mosquito vectors and increased long-distance travel have contributed to the increase and spread of dengue disease. The characteristics of dengue virus as a viral hemorrhagic fever virus (arthropod transmission, widespread spread, and the ability to induce extensive cellular damage and trigger an immune response that can lead to severe hemorrhage, shock, and death) make it a unique threat to military personnel deployed around the world and travelers to tropical regions. To address the biodefense and public health challenges posed by dengue fever, new vaccines and antiviral therapies will be needed.

[0006] Dengue fever causes several illnesses, the severity of which depends in part on the different serotypes of the virus previously contracted. Typical dengue fever (DF) begins 3–8 days after an infected mosquito bite and is characterized by a sudden onset of fever, headache, back pain, joint pain, measles-like rash, and nausea and vomiting. DF is often called “breakbone” fever because of these symptoms. The illness usually subsides after two weeks, but the recovery period is long and is often accompanied by weakness and depression.

[0007] DHF is a more severe form of the disease, with an onset and early stages similar to dengue. However, shortly after onset, the disease is characterized by high fever, hepatomegaly, and bleeding phenomena due to vascular permeability (such as nosebleeds, oral bleeding, and visceral bleeding). In DSS, circulatory failure and hypovolemic shock due to plasma leakage occur, and death can occur within 12–24 hours without plasma exchange, as described on page 1 / 81 of the specification (CN 121358746 A). Without treatment, the mortality rate of DHF / DSS can be as high as 20%. DHF has become a leading cause of hospitalization and death in children in many countries, with an estimated 500,000 hospitalizations annually and a mortality rate of approximately 5%.

[0008] The pathogenesis of DHF / DSS is still under investigation, but it is believed to be partly related to heterologous antibody-enhanced viral replication in macrophages, a phenomenon known as antibody-dependent enhancement (ADE). Specifically, during secondary infection with different serotypes of dengue virus, non-neutralizing cross-reactive antibodies form virus-antibody complexes that facilitate viral uptake of monocytes and Langerhans cells (dendritic cells) in an Fc-mediated manner, increasing the number of infected cells. This leads to cellular...Activation of toxic lymphocytes, which can lead to plasma leakage and the hemorrhagic features characteristic of DHF and DSS. This antibody-dependent enhancement of infection is one reason why successful vaccines are so difficult to develop. Although less common, DHF / DSS can occur after primary infection, so viral virulence and immune activation are also thought to contribute to the pathogenesis of the disease.

[0009] Dengue fever is prevalent in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. During an epidemic, the attack rate can be as high as 80-90% of the susceptible population. All four serotypes of the virus are present worldwide, increasing the number of cases and outbreaks of the disease. For example, in 2002, 1,015,420 cases of dengue fever were reported in the Americas alone, of which 14,374 were DHF, more than three times the number of dengue fever cases reported in the Americas in 1995.

[0010] The dengue virus genome consists of a linear single-stranded positive-sense RNA of approximately 11 kb in length. This genome is capped and lacks a 3' end with a poly(A) tail, instead possessing a stable stem-loop structure necessary for the stability of viral genomic RNA and replication. Three structural proteins, namely nucleocapsid protein (C), membrane-associated protein (M), and envelope protein (E), surround the viral RNA and constitute the virion.

[0011] During infection, the virus binds to a cell receptor via the E protein and undergoes receptor-mediated endocytosis, followed by low-pH fusion in the lysosome. The virion then uncoats, releasing viral RNA into the cytoplasm and translating it into a single viral precursor polyprotein. This polyprotein consists of three structural proteins, C, M, and E, and seven non-structural (NS) proteins. The precursor polyprotein is cleaved by cellular proteases to separate the structural proteins, while viral-encoded proteases cleave the non-structural regions of the polyprotein. Co-translation and post-translational proteolytic processing both separate the viral proteins. Specifically, the structural proteins are primarily involved in viral particle formation, while the non-structural proteins are involved in viral RNA replication and viral assembly, as well as immune regulation and contributing to disease pathogenesis.

[0012] Nonstructural protein 5 (NS5) constitutes an RNA-dependent RNA polymerase, which, along with cofactors, synthesizes negative-strand RNA that serves as a template for the synthesis of progeny positive-strand RNA. Viral replication is membrane-associated and occurs in specific endoplasmic reticulum (ER)-derived subcellular compartments. After replication, the genome is capsidated, and the immature virus, surrounded by a lipid envelope, buds into the ER lumen, is transported across the TGN, where envelope proteins are glycosylated, and finally, mature virus is released onto the cell surface.

[0013] Essential stages or processes during the viral life cycle may be potential targets for antiviral drug inhibition, including viral binding to cells via E proteins, viral uptake of cells, capping mechanisms, viral proteases, viral RNA-dependent RNA polymerase, and viral helicases.

[0014] Currently, the control of dengue virus-related diseases relies solely on vector control. No antiviral drugs or vaccines have been approved for the treatment or prevention of dengue fever.

[0015] Ribavirin, a guanosine analogue, has been shown to be effective against a range of RNA virus infections and exerts its anti-dengue effect in tissue cultures by inhibiting the dengue 2'-O-methyltransferase NS5 domain. However, ribavirin has not shown protective effects against dengue in mouse or rhesus monkey models, instead inducing anemia and thrombocytosis. While some antiviral candidates targeting DENV NS4B are currently in clinical trials (i.e., JNJ-1802, NITD-688), they have not yet been approved for treatment, and the possibility of resistance to directly acting antiviral drugs poses a serious and ongoing threat to RNA viruses. This can only be overcome by developing antiviral molecules with alternative mechanisms of action, thus urgently requiring further development of antiviral candidates targeting this pathogen.

[0016] Currently, there are two approved vaccines available (Dengvaxia and QDENGA). Dengvaxia is only recommended for people who have previously had dengue fever. QDENGA was recently approved in Indonesia and the European Union. In general, multivalent dengue vaccines have shown some limited potential in humans due to the existence of four different viral serotypes, each of which causes disease, which presents challenges. Vaccine development also faces the challenge of ADE, where unequal protection against the four viral serotypes may actually increase the risk of more severe disease.

[0017] Therefore, there is a need to develop antiviral drugs that target all dengue virus serotypes. Antiviral drugs that inhibit viral replication and are administered early during dengue infection will prevent high viral loads associated with DHF and are a strategy worth considering for the treatment and prevention of the disease. Antiviral drugs that inhibit viral replication and are administered before traveling to dengue-endemic areas can be used as a preventative measure to prevent infection, or for people who have been previously exposed to dengue virus, to prevent infection with another viral serotype and reduce the chance of developing life-threatening DHF and DSS. Having antiviral drugs would also aid vaccine development, as they could serve as readily available tools to treat complications that may arise from unequal immune protection against different serotypes. While a successful vaccine could be a key component of effective biodefense, the typical delays in immune onset, potential side effects, cost, and logistics associated with mass civilian vaccination against low-threat risk factors suggest that comprehensive biodefense includes individual rapid response elements.

[0018] Therefore, the need to develop effective therapies for treating dengue virus is evident and has been long-standing.Specifically, there is a need to develop compounds that can be used to treat patients with dengue fever infection and compounds that selectively inhibit dengue virus replication.

[0019] Figure 1. Summary of antiviral activities of Example 1 and other known nucleoside compounds (Nucs).

[0020] Figure 2. Comparison of selective antiviral activity of compound 58 with AL-611.

[0021] This disclosure provides compounds of formula (I) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O) (C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl (Specification 3 / 81 page 17 CN 121358746 A (C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')2、-P(=O)(OR 1')-P(=O)(OR1')-P(= O)(OR1')2、-P(=O)(OR 1')NH(C1-C6)alkyl、-P(=O)(OR1')NH(C1-C6)heteroalkyl、-P(=O)(OR1')NH(C1-C6)haloalkyl、-P(=O)(OR1')NH(C3-C7)cycloalkyl、-P(=O)(OR1')NH(C3-C7)heterocycloalkyl、-P(=O) (OR1')NH(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O)(NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocycloalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8) Heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O- (C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; Each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl, or -(C1-C6)alkyl(C5-C8)heteroaryl; R2a is H, halo, (C1-C6)alkyl, or -C≡CH; R2b is independently halo or OH; R3 is independently H or OH; R4 is N3, halo, -C≡N, (C1-C3) haloalkyl or -O (C1-C6) alkyl;R5 is H, halogenated, -C≡N, (C1-C6)alkyl, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, N(R1')2, -C(=O)NH2; R6 is H, halogenated, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)ynyl; R7 is H, NH2, OH, halogenated, oxo, N(R1')2, or -O(C1-C6)alkyl; and R8 is H or halogenated; provided that the compound of formula I is not 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; 5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxynitrile; ((5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; ((5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; ((5-(4-amino-5-fluoro-7H-pyrrolo[2,3-) (5-(4-amino-5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; (5-(4-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5- Fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2S,3S, 4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; including enantiomers, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

[0022] This disclosure further provides compounds having the formula (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol.

[0023] The disclosure further provides compounds having the formula ((R)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester.

[0024] This disclosure further provides pharmaceutical compositions comprising a mixture of the compound as described in any one of embodiments 1-38 (hereinafter) with a pharmaceutically acceptable carrier, diluent, or excipient.

[0025] This disclosure further provides the above-described pharmaceutical compositions, which further comprise one or more therapeutic compounds or compositions.

[0026] This disclosure further provides the above-described pharmaceutical compositions, wherein one or more of the therapeutic compounds or compositions are second antiviral compounds or compositions.

[0027] This disclosure further provides a method for inhibiting RNA-dependent RNA polymerase, comprising administering to a subject in need a therapeutically effective amount of a compound as described in any one of embodiments 1-38 (hereinafter) or a pharmaceutical composition as described in embodiments 39-43 (hereinafter).

[0028] This disclosure further provides a method for preventing, improving, or treating RNA virus infection, comprising administering to a subject in need a therapeutically effective amount of a compound as described in any one of embodiments 1-38 (hereinafter) or a pharmaceutical composition as described in embodiments 39-43 (hereinafter).

[0029] This disclosure further provides the above method, wherein the RNA virus infection is at least one virus selected from the following: dengue virus, South Asian respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, Zika virus, yellow fever virus, Ebola (Macona) virus, Ebola (Kikute) virus, Bundibugyo virus, Sudan virus, Marburg virus, respiratory syncytial virus (RSV), Nipah virus, measles virus, parainfluenza virus, Middle East respiratory syndrome (MERS) virus, hepatitis C virus (HCV), West Nile virus, Lassa virus, influenza, HRV, MEV, LCMV, polio, CHIKV, COXV, and Junin virus.

[0030] This disclosure further provides the above method, wherein the RNA virus infection is caused by dengue virus, SARS-CoV-2 virus, yellow fever virus, or Zika virus. Detailed Description

[0031] RNA-dependent RNA polymerase (RdRp) is an important therapeutic target for treating diseases caused by RNA viruses becauseRdRp is an enzyme essential for the replication of the viral RNA genome, and the host lacks a functional equivalent. Nucleosides and nucleotide analogs have been well reported as successful antiviral strategies targeting RdRp (i.e., sofosbuvir and remdesivir). Nucleoside analogs are converted into active 5'-triphosphate metabolites, which in turn inhibit viral replication.

[0032] What we disclose here is that we have discovered 4'-substituted nucleosides and nucleotides with good antiviral activity against dengue virus (DENV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Tuberculin (kCBN048) was confirmed from screening to have high antiviral efficacy against DENV and SARS-CoV-2, but significant cytotoxicity. NITD-008 (kCMY389) is a reported tuberculin analogue with a 2'-β-methyl substitution and exhibits improved selectivity compared to tuberculin (SIkCMY389=52 vs. SIkCBN048=2, DENV-2 HepG2 assay, Figure 1). NITD-008 showed good efficacy in a mouse model of DENV infection but failed in a two-week toxicity study. Our strategy is to utilize 4'-substitution to enhance the selectivity and activity of tuberculin. Compound 1, with a 4'-F substitution, showed improved activity and selectivity compared to tuberculin and NITD-008 (SIkCMY389=73 vs. SIkCBN048=2, SIkCMY389=52; DENV-2 HepG2 assay, Table 1). Compound 1 and its analogues may be used to treat DENV, COVID-19, and other RNA virus infections. SAR studies are underway focusing on nucleobases, sugar rings, and prodrug strategies to improve selectivity, activity, and physicochemical properties. For example, compound 1 was found to be more effective than RDV parent nucleoside and N-hydroxycytidine in flaviviruses (DENV-2, ZIKV, YFV), respiratory viruses (SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-OC43, HCoV-229E, HRV14, HRV16, MEV, RSV A2, influenza A H1N1, alpha virus CHIKV), and enteroviruses (poliovirus PV-1, poliovirus PV-3, COXV-B3) (Figure 1). Additionally, compound 58 was found to be more effective than AL-611 in HRV-14, HRV-16, and DENV-2 (Figure 2).

[0033] Currently, there are no antiviral treatments for dengue fever on the market. Although remdesivir and monoupivir are approved by the FDA for antiviral treatment of COVID-19 with the same MOA, remdesivir must be administered intravenously (IV).Monupivvir is administered orally, and it has been reported to have potential mutagenic toxicity. There is a need to develop novel antiviral drugs (oral medications) with better safety and patient compliance. Lead compound 1 showed improved activity and selectivity compared to known compounds with the same mechanism of action (MOA) against DENV and SARS-CoV-2.

[0034] Embodiment 1. A compound of formula (I) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O) (C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2, -P(=O)(OR1')2 1')-P(=O)(OR1')-P(= O)(OR1')2、-P(=O)(OR 1')NH(C1-C6)alkyl、-P(=O)(OR1')NH(C1-C6)heteroalkyl、-P(=O)(OR1')NH(C1-C6)haloalkyl、-P(=O)(OR1')NH(C3-C7)cycloalkyl、-P(=O)(OR1')NH(C3-C7)heterocycloalkyl、-P(=O) (OR1')NH(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O)(NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocycloalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8) Heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl- Specification 6 / 81 pages 20 CN 121358746 AC(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O- (C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; Each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl, or -(C1-C6)alkyl(C5-C8)heteroaryl; R2a is H, halo, (C1-C6)alkyl, or -C≡CH; R2b is independently halo or OH; R3 is independently H or OH; R4 is N3, halo, -C≡N, (C1-C3) haloalkyl or -O (C1-C6) alkyl;R5 is H, halogenated, -C≡N, (C1-C6)alkyl, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, N(R1')2, -C(=O)NH2; R6 is H, halogenated, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)ynyl; R7 is H, NH2, OH, halogenated, oxo, N(R1')2, or -O(C1-C6)alkyl; and R8 is H or halogenated; provided that the compound of formula I is not 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; 5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxynitrile; ((5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; ((5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; ((5-(4-amino-5-fluoro-7H-pyrrolo[2,3-) (5-(4-amino-5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; (5-(4-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5- Fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; comprising enantiomers, racemic and non-racemic mixtures, and further comprising pharmaceutically acceptable salts thereof.

[0035] Embodiment 2. A compound of formula (II) specification 7 / 81Page 21 CN 121358746 A Wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O) (C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2, -P(=O)(OR1')2 1')-P(=O)(OR1')-P(= O)(OR1')2、-P(=O)(OR 1')NH(C1-C6)alkyl、-P(=O)(OR1')NH(C1-C6)heteroalkyl、-P(=O)(OR1')NH(C1-C6)haloalkyl、-P(=O)(OR1')NH(C3-C7)cycloalkyl、-P(=O)(OR1')NH(C3-C7)heterocycloalkyl、-P(=O) (OR1')NH(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O) (NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocycloalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1') NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(= O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8) Heteroaryl or -(C1-C6)alkyl (C5-C8)heteroaryl; R2 is H, (C1-C6)alkyl or -C≡CH; R4 is N3, halo or -O(C1-C6)alkyl; R5 is H, halo, -C≡N, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, N(R1')2, -C(=O)NH2; R6 is H, halo, NH2, (C1-C6)alkyl, (C2-C6)alkenyl or (C2-C6)ynyl; R7 is H, NH2, OH, halo, N(R1')2 or -O(C1-C6)alkyl; and R8 is H or halo; the condition is that the compound of formula II is not (2S,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triTriazine-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3S,4R,5S)-5-(4-amino-5-fluoropyrrolo[2,1-f][1,2,4]triazine-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl-5-d)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate or ((((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-D-alanine 2-ethylbutyl ester; Includes enantiomers, racemic and non-racemic mixtures, and further includes pharmaceutically acceptable salts thereof.

[0036] Embodiment 3. A compound of formula (IIIa) or (IIIb) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O) (C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2、-P(=O)(OR 1')-P(=O)(OR1')-P(= O)(OR1')2、-P(=O)(OR 1')NH(C1-C6)alkyl、-P(=O)(OR1')NH(C1-C6)heteroalkyl、-P(=O)(OR1')NH(C1-C6)haloalkyl、-P(=O)(OR1')NH(C3-C7)cycloalkyl、-P(=O)(OR1')NH(C3-C7)heterocycloalkyl、-P(=O) (OR1')NH(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O) (NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocycloalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8) Heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O- (C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl;Each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)ene, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R2a is H, OH, halo, (C1-C6)alkyl, or -C≡CH; R2b is H, OH, halo, or (C1-C6)alkyl; R3a is H, OH, halo, or (C1-C6)alkyl; R3b is H, OH, halo, or (C1-C6)alkyl; R4 is N3, halo, -C≡N, (C1-C3)haloalkyl, or -O(C1-C6)alkyl; R6 and R6' are each independently halo, NH2, NH(C1-C6)alkyl, N((C1-C6)alkyl)2, -OH, -O(C1-C6)alkyl, -oxo, or -C≡CH; and R8 is H or halo; The condition is that the compound of formula III is not (((2R,3S,4R,5R)-5-(2,6-diamino-9H-purine-9-yl)-2- (difluoromethyl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; (((2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphate; (2S,3S,4R,5R)-5-(2,6-diamino-9H-purin-9-yl)-2-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; Includes enantiomers, racemic and non-racemic mixtures, and further includes pharmaceutically acceptable salts thereof.

[0037] Embodiment 4. A compound of formula (IV) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heterocycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heterocycloalkyl, and -C(=O)(C1-C6)alkyl(C3-C7)heterocycloalkyl.aryl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O)(C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C =O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl, -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')-P(=O)(OR1')2, P(=O)(OR 1')NH(C1- C6) haloalkyl, -P(=O)(OR1')NH(C3-C7)cycloalkyl, -P(=O)(OR1')NH(C3-C7)heterocycloalkyl, -P(=O)(OR1')NH(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O) (NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, Specification 10 / 81 pages 24 CN 121358746 A group, -P(=O)(NHR1')NH(C3-C7)heterocyclic alkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8) Heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl, -C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl, -C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl, -C(=O)O- (C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; Each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkylynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl, or -(C1-C6)alkyl(C5-C8)heteroaryl; R4 is N3, halo, or -O (C1-C6) alkyl; and R6 is H, halo, (C1-C6) alkyl, (C2-C6) alkenyl, or (C2-C6) ynyl; including enantiomers, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

[0038] Embodiment 5. A compound of formula (V) wherein: R1 is selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C10)aryl, -C(=O)(C1-C6)alkyl(C6-C10)aryl, -C(=O)(C5-C8)heteroaryl, -C(=O) (C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)Alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C10)aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')2, -P(=O)(OR 1')-P(=O)(OR1')-P(=O)(OR1')2, -P(=O)(OR 1')NH(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl, -P(=O)(OR1')NH(C3-C7)cycloalkyl, -P(=O)(OR1')NH(C3-C7)heterocycloalkyl, -P(=O)(OR1')NH(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C5-C8)heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl, -P(=O) (NHR1')NH(C1-C6)heteroalkyl, -P(=O)(NHR1')NH(C1-C6)haloalkyl, -P(=O)(NHR1')NH(C3-C7)cycloalkyl, -P(=O)(NHR1')NH(C3-C7)heterocycloalkyl, -P(=O)(NHR1')NH(C6-C10)aryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C6-C10)aryl, -P(=O)(NHR1')NH(C5-C8)heteroaryl, -P(=O)(NHR1')NH(C1-C6)alkyl(C5-C8) Heteroaryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)heteroalkyl- Specification 11 / 81 Page 25 CN 121358746 AC(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C1-C6)alkyl(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)alkyl-C(=O)O-(C6-C10)aryl, -P(=O)(OR1')NH(C1-C6)heteroalkyl-C(=O)O-(C6-C10)aryl and -P(=O)(OR1')NH(C1-C6)haloalkyl-C(=O)O-(C6-C10)aryl; Each R1' is independently H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroalkyl, -(C2-C6)haloalkylynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C10)aryl, -(C1-C6)alkyl(C6-C10)aryl, -(C5-C8)heteroaryl, or -(C1-C6)alkyl(C5-C8)heteroaryl; R2 is H, halo, (C1-C6)alkyl, or -C≡CH; R4 is N3, halo, -C≡N, (C1-C3)haloalkyl, or -O(C1-C6)alkyl; R5 is H, halo, -C≡N, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, N(R1')2, -(C(=O)NH2; R6 is H, halo, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)ynyl; R7 is H, NH2, OH, halo, N(R1')2, or -O(C1-C6)alkyl; and R8 is H or halo; including enantiomers, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

[0039] Embodiment 6. The compound as described in Embodiment 1, wherein R2b is OH or halo.

[0040] Embodiment 7. The compound of embodiment 3, wherein R2b is halogenated.

[0041] Embodiment 8. The compound of embodiment 7, wherein R2a is Me or halogenated.

[0042] Embodiment 9. The compound of any one of embodiments 6-8, wherein R2a is H.

[0043] Embodiment 10. The compound of any one of embodiments 6-8, wherein R2a is (C1-C6) alkyl.

[0044] Embodiment 11. The compound of embodiment 10, wherein R2a is Me.

[0045] Embodiment 12. The compound of any one of embodiments 6-8, wherein R2a is halogenated.

[0046] Embodiment 13.The compound of embodiment 12, wherein R2a is Cl.

[0047] Embodiment 14. The compound of any one of embodiments 2 or 5, wherein R2 is H.

[0048] Embodiment 15. The compound of any one of embodiments 2 or 5, wherein R2 is halogenated.

[0049] Embodiment 16. The compound of embodiment 15, wherein R2 is F.

[0050] Embodiment 17. The compound of any one of embodiments 2 or 5, wherein R2 is (C1-C6) alkyl.

[0051] Embodiment 18. The compound of embodiment 17, wherein R2 is Me.

[0052] Embodiment 19. The compound of any one of embodiments 1-2 or 5, wherein R5 is H.

[0053] Embodiment 20. The compound of any one of embodiments 1-2 or 5, wherein R5 is -CH2OH.

[0054] Embodiment 21. The compound of any one of embodiments 1-2 or 5, wherein R5 is -C(=O)NH2.

[0055] Embodiment 22. The compound of any one of Embodiments 1, 6-13 or 19-21, wherein R3 is OH.

[0056] Embodiment 23. The compound of any one of Embodiments 1, 6-13 or 19-21, wherein R3 is H.

[0057] Embodiment 24. The compound of any one of Embodiments 1-23, wherein R4 is halogenated.

[0058] Embodiment 25. The compound of Embodiment 24, wherein R4 is F.

[0059] Embodiment 26. The compound of Embodiment 24, wherein R4 is Cl. Specification 12 / 81 pages 26 CN 121358746 A

[0060] Embodiment 27. The compound of any one of Embodiments 1-23, wherein R4 is N3.

[0061] Embodiment 28. The compound of any one of Embodiments 1-23, wherein R4 is -O(C1-C6) alkyl.

[0062] Embodiment 29. The compound of Embodiment 28, wherein R4 is -OMe.

[0063] Embodiment 30. The compound of any one of Embodiments 1-29, wherein R6 is H or NH2, and R6' is -NH(C1-C6)alkyl or -O(C1-C6)alkyl. Embodiment 31. The compound of any one of Embodiments 1-29, wherein R6 is halogenated.

[0064] Embodiment 32. The compound of Embodiment 31, wherein R6 is F.

[0065] Embodiment 33. The compound of any one of Embodiments 1-29, wherein R6 is -C≡CH.

[0066] Embodiment 34.The compound of any one of embodiments 1-33, wherein R1 is H.

[0067] Embodiment 35. The compound of any one of embodiments 1-33, wherein R1 is -P(=O)(OR1')2, -P(=O)(OR1')-P(=O)(OR1')2 or -P(=O)(OR1')-P(=O)(OR1')-P(=O)(OR1')2.

[0068] Embodiment 36. The compound of any one of embodiments 1-33, wherein R1 is -P(=O)(OR1')NH (C1-C6)alkyl-C(=O)O-(C1-C6)alkyl.

[0069] Embodiment 37. A compound having any of the following formulas: (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-(hydroxymethyl)-2-methoxy-4-methyltetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3R,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-chloro-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R (2R,3R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-4-chloro-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3S,4R,5S)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-azido-5-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-2-(hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol;(2R,3R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol; (2S,3S,4R,5R)-2-fluoro-5-(4-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; Specification 13 / 81 Page 27 CN 121358746 A 4-Amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; (2S,3S,4R,5R)-5-(4-amino-5-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(6-amino-2-ethynyl-9H-purine-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5S)-5-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(fluoromethyl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 5-fluoro-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; (2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-fluoro-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2S,3S,4R,5R)-5-(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-carboxynitrile; (2S,3S,4R,5R)-5-(2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(6-(methylthio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (1S,2S,3S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-3-(hydroxymethyl)cyclopentane-1,2-diol; (2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purine-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrofuran-2-carboxynitrile; Specification 14 / 81 pages 28 CN 121358746 A (2S,3S,4R,5R)-5-(4-amino-5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; benzoic acid ((2S,3S,4R,5S)-5-(4-amino-5-carbamoylpyrrolo[2,1-f][1,2,4]triazine-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; (2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-carboxynitrile;7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-carboxamide; (2R,3R,5R)-5-fluoro-5-(hydroxymethyl)-2-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3-ol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-amino-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(6-amino-2-chloro-9H-purine-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 4-amino-1-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; (2S,3S,4R,5R)-2-((benzoyloxy)methyl)-5-(3,5-dioxo-4,5-dihydro-1,2,4-triazine-2(3H)-yl)-2-fluorotetrahydrofuran-3,4-dimethyldiacetate; Isobutyric acid ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-dimethylbis(2-methylpropionate); ((S)-(((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((R)-(((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; Benzoic acid ((2S,3S,4R,5R)-4-(benzoyloxy)-5-(4-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl) (2R,3R,4S,5S)-2-(4-aminoimidazo[2,1-f][1,2,4]triazine-7-yl)-5-fluoro-3,4-dihydroxy(2S,3S,4R,5R)-5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3R,5R)-5-(4-amino-5-(benzo[d]thiazolyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,4,4-trifluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; benzoic acid ((2S,3S,4R,5R)-5-(2-amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; (2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-chloro-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; ((R)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((S)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; (2S,3R,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-2,4,4-trifluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; ((((2S,3R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-2,4,4-trifluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; 2-amino-9-((2R,3R,4R,5S)-3-chloro-5-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one; (2S,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol;((((2S,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((((2S,3S,4R,5R)-5-(4-aminoimidazo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(naphthyl-1-yloxy)phosphoryl)-L-alanine neopentyl ester; (2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; ((((2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; 2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-4-bromo-2,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; ((((2S,3R,5R)-5-(2-amino-6-ethoxy-9H-purine-9-yl)-2,4,4-trifluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; (2S,3S,4R,5R)-4-ethynyl-2-fluoro-2-(hydroxymethyl)-5-(4-(propylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; 2-amino-9-((2R,4R,5S)-3,3,5-trifluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purine-6-one; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; Specification 16 / 81 pages 30 CN 121358746 AL-valine ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl) methyl ester; ((((2S,3S,4R,5R)-5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(naphthyloxy)phosphoryl)-L-alanine neopentyl ester; ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(naphthyloxy)phosphoryl)-L-alanine neopentyl ester; ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)((2S,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-2-fluoro-3,4-dihydroxy-5-(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(4-aminoimidazo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(4-amino-5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate; ((2S,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purine-9-yl)-4-chloro-2-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyltetrahydrotriphosphate; and ((2S,3S,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methyltetrahydrotriphosphate.

[0070] Embodiment 38. The compound as described in Embodiment 37, having the chemical formula (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol or ((R)-(((2S, 3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-(2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester.

[0071] Embodiment 39. A pharmaceutical composition comprising a compound as described in any one of Embodiments 1-38, mixed with a pharmaceutically acceptable carrier, diluent, or excipient.

[0072] Embodiment 40. A pharmaceutical composition as described in Embodiment 39, further comprising one or more therapeutic compounds or compositions.

[0073] Embodiment 41. A pharmaceutical composition as described in Embodiment 40, wherein the one or more therapeutic compounds or compositions are second antiviral compounds or compositions.

[0074] Embodiment 42. A pharmaceutical composition as described in Embodiment 41, wherein the second antiviral compound or composition is an RdRp inhibitor.

[0075] Embodiment 43. A pharmaceutical composition as described in Embodiment 41, wherein the second antiviral compound or composition is an RNA polymerase inhibitor.

[0076] Embodiment 44. A method for inhibiting RNA-dependent RNA polymerase, comprising administering to a subject in need a therapeutically effective amount of a compound as described in any one of Embodiments 1-38 or a pharmaceutical composition as described in Embodiments 39-43.

[0077] Embodiment 45. A method for preventing, improving, or treating RNA virus infection, comprising administering to a subject in need a therapeutically effective amount of a compound as described in any one of Embodiments 1-38 or a pharmaceutical composition as described in Embodiments 39-43.

[0078] Embodiment 46. The method of Embodiment 45, wherein the RNA virus infection is at least one virus selected from the group consisting of: dengue virus, South Asian respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, Zika virus, yellow fever virus, Ebola (Macona) virus, Ebola (Kikut) virus, Bundibugyo virus, Sudan virus, Marburg virus, respiratory syncytial virus (RSV), Nipah virus, measles virus, parainfluenza virus, Middle East respiratory syndrome (MERS) virus, hepatitis C virus (HCV), West Nile virus, Lassa virus, influenza, HRV, MEV, LCMV, polio, CHIKV, COXV, and Junin virus.

[0079] Embodiment 47. The method of Embodiment 46, wherein the RNA virus infection is caused by dengue virus.

[0080] Embodiment 48. The method of Embodiment 46, wherein the RNA virus infection is caused by SARS-CoV-2 virus.

[0081] Embodiment 49. The method as described in Embodiment 46, wherein the RNA virus infection is caused by yellow fever virus.

[0082] Embodiment 50.The method of embodiment 46, wherein the RNA virus infection is caused by Zika virus.

[0083] Embodiment 51. The method of any one of embodiments 44-50, further comprising treatment with one or more additional therapeutic compounds or compositions.

[0084] Embodiment 52. The method of embodiment 51, wherein at least one of the one or more therapeutic compounds or compositions is an effective medicine for treating or improving RNA virus infection.

[0085] Embodiment 53. The method of embodiment 52, wherein the medicine for treating RNA virus infection is selected from remdesivir, monoprevir, or parovir.

[0086] Embodiment 54. Any compound, composition, or method described herein.

[0087] Definitions as used herein, the term “comprising” is to be interpreted in an open-ended sense, whether in transitional phrases or in the body of the claims. That is, the term is to be interpreted as synonymous with the phrase “having at least” or “including at least”. The term "comprising" when used in the context of a method means that the method includes at least the listed steps, but may include additional steps. The term "comprising" when used in the context of a compound or composition means that the compound or composition includes at least the listed features or components, but may also include additional features or components.

[0088] As used herein, unless expressly indicated otherwise, the word "or" is used in an inclusive sense of "and / or" rather than in an exclusive sense of "either / or".

[0089] The term "independently" is used herein to indicate that a variable is applied in any case without regard to the presence or absence of variables having the same or different definitions within the same compound. Thus, in compounds in which "R" appears twice and is defined as "independently selected", it means that each occurrence of the R group is individually identified as a member of the set conforming to the definition of the R group. For example, "each R1 and R2 is independently selected from carbon and nitrogen" means that both R1 and R2 can be carbon, R1 and R2 are carbon, and R2 are carbon. Specification 18 / 81 pages 32 CN 121358746 A All can be nitrogen, or R1 or R2 can be carbon and the other is nitrogen, or vice versa.

[0090] When any variable appears more than once in any part or chemical formula of a compound used in or claimed in the description and illustration of this invention, its definition for each occurrence is independent of its definition for each subsequent occurrence. Moreover, combinations of substituents and / or variables are permitted only if such compounds produce stable compounds.

[0091] The symbol “*” at the end of a bond or a line drawn through a bond or a “~~~~” drawn through a bond each refers to the point of connection between a functional group or other chemical part and the rest of the molecule to which it belongs.

[0092] A bond drawn into a ring system (as opposed to a bond connected at an exact vertex) indicates that the bond can be attached to any suitable ring atom.

[0093] The terms “optional” or “optionally” as used herein mean that an event or condition described below may occur but does not have to occur, and the description includes instances where the event or condition occurs and instances where it does not occur. For example, “optionally substituted” means that the “optionally substituted” portion may contain hydrogen or a substituent.

[0094] The phrase “optional bond” means that the bond may be present or may not be present, and the description includes single, double, or triple bonds. If a substituent is specified as a “bond” or “not present,” the atom attached to the substituent is directly connected.

[0095] The term “about” as used herein means approximately, roughly, probably, or about. When the term “about” is used in conjunction with a numerical range, it modifies the range by extending the upper and lower limits of the listed numerical values. Generally, the term “about” is used herein to modify the numerical values ​​that fluctuate by 20%.

[0096] Some compounds disclosed herein may exhibit tautomerism. Tautomers can exist in the form of two or more interconvertible substances. Proton transfer tautomers arise from the migration of covalently bonded hydrogen atoms between two atoms. Tautomers typically exist in equilibrium, and attempts to separate individual tautomers usually yield mixtures with chemical and physical properties consistent with those of the compound. The position of equilibrium depends on the intramolecular chemical signature. For example, in many aliphatic aldehydes and ketones (such as acetaldehyde), the ketone form is dominant; while in phenols, the enol form is dominant. Common proton transfer tautomers include ketone / enol (-C(=O)-CH--C(-OH)=CH-), amide / imine (-C(=O)-NH--C(-OH)=N-), and amidine (-C(=NR)-NH--C(-NHR)=N-) tautomers. The latter two are particularly common in heteroaryl and heterocyclic compounds, and this invention covers all tautomeric forms of said compounds.

[0097] Unless otherwise defined, the technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains. Various methods and substances known to those skilled in the art are mentioned herein. Standard references explaining general principles of pharmacology include *The Pharmacological Basis of Therapeutics*, 10th edition, McGraw Hill Companies Inc., New York (2001), by Goodman and Gilman. Any suitable substance and / or method known to those skilled in the art may be used to practice this invention. However, preferred substances and methods are described herein. Unless otherwise stated, the substances, reagents, etc., mentioned in the following description and examples are commercially available.

[0098] The definitions described herein can be appended to form chemically related combinations, such as “heteroalkylaryl,” “haloalkylheteroaryl,” “arylalkylheterocyclic,” “alkylcarbonyl,” “alkoxyalkyl,” etc. When the term “alkyl” is used as a suffix following another term, such as in “phenylalkyl” or “hydroxyalkyl,” this is intended to refer to an alkyl group as defined above that is substituted with one or two substituents selected from other specifically named groups. Thus, for example, “phenylalkyl” refers to an alkyl group having one or two phenyl substituents, and therefore includes benzyl, phenethyl, and biphenyl. “alkylaminoalkyl” is an alkyl group having one or two alkylamino substituents. “Hydroxyalkyl” includes 2-hydroxyethyl, 2-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 2,3-dihydroxybutyl, 2-(hydroxymethyl), 3-hydroxypropyl, etc. Therefore, as used herein, the term “hydroxyalkyl” is used to define a subset of heteroalkyl groups as defined below. The term –(aryl)alkyl refers to an unsubstituted alkyl or arylalkyl group. The term “(hetero)aryl” refers to an aryl or heteroaryl group. Specification 19 / 81, page 33, CN 121358746 A

[0099] As used herein, the term “acyl” represents a group of the formula -C(=O)R, where R is hydrogen or a lower alkyl group as defined herein. As used herein, the term “alkylcarbonyl” represents a group of the formula C(=O)R, where R is an alkyl group as defined herein. The term C1-6 acyl means that the group -C(=O)R contains 6 carbon atoms. As used herein, the term “arylcarbonyl” means a group of the formula C(=O)R, where R is an aryl group; the term “benzoyl” as used herein means “arylcarbonyl”, where R is a phenyl group.

[0100] As used herein, the term “alkyl” represents a non-branched or branched saturated monovalent hydrocarbon residue containing 1 to 12 carbon atoms. As used herein, the terms “lower alkyl” or “C1-C6 alkyl” refer to straight-chain or branched hydrocarbon residues containing 1 to 6 carbon atoms. As used herein, “C1-12 alkyl” refers to an alkyl group consisting of 1 to 12 carbon atoms. Examples of alkyl groups include, but are not limited to, lower alkyl groups, including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.

[0101] When the term “alkyl” is used as a suffix following another term, such as in “phenylalkyl” or “hydroxyalkyl”, this is intended to refer to an alkyl group as defined above that is substituted with one or two substituents selected from other specifically named groups. Thus, for example, “phenylalkyl” indicates a group R'R"-, where R' is phenyl and R" is an alkylene group as defined herein, and it is to be understood that the phenylalkyl moiety will be connected at the alkylene group. Examples of arylalkyl groups include, but are not limited to, benzyl, phenethyl, and 3-phenylpropyl. The terms "arylalkyl" or "aralkyl" are interpreted similarly, except that R' is aryl. The terms "(hetero)arylalkyl" or...The interpretation of “(hetero)arylalkyl” is similar, except that R' is optionally aryl or heteroaryl.

[0102] When a range of values ​​is listed, it is intended to cover every value and subrange within that range. For example, “C1-6 alkyl” is intended to cover C1, C2, C3, C4, C5, C6, C1–6, C1–5, C1–4, C1–3, C1–2, C2–6, C2–5, C2–4, C2–3, C3–6, C3–5, C3–4, C4–6, C4–5, and C5–6 alkyl.

[0103] “alkyl” refers to a straight-chain or branched saturated hydrocarbon group having 1 to 20 carbon atoms (“C1-20 alkyl”). In some embodiments, the alkyl has 1 to 15 carbon atoms (“C1-15 alkyl”). In some embodiments, the alkyl has 1 to 14 carbon atoms (“C1-14 alkyl”). In some embodiments, the alkyl group has 1 to 13 carbon atoms (“C1-13 alkyl”). In some embodiments, the alkyl group has 1 to 12 carbon atoms (“C1-12 alkyl”). In some embodiments, the alkyl group has 1 to 11 carbon atoms (“C1-11 alkyl”). In some embodiments, the alkyl group has 1 to 10 carbon atoms (“C1-10 alkyl”). In some embodiments, the alkyl group has 1 to 9 carbon atoms (“C1-9 alkyl”). In some embodiments, the alkyl group has 1 to 8 carbon atoms (“C1-8 alkyl”). In some embodiments, the alkyl group has 1 to 7 carbon atoms (“C1-7 alkyl”). In some embodiments, the alkyl group has 1 to 6 carbon atoms (“C1-6 alkyl”). In some embodiments, the alkyl group has 1 to 5 carbon atoms (“C1-5 alkyl”). In some embodiments, the alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”). In some embodiments, the alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”). In some embodiments, the alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In some embodiments, the alkyl group has 1 carbon atom (“C1 alkyl”). In some embodiments, the alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”). Examples of C1-6 alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). Other examples of alkyl groups include n-heptyl (C7), n-octyl (C8), etc.

[0104] “Alkenyl” or “olefin” refers to a straight or branched chain having 2 to 10 carbon atoms and 1, 2, 3, or 4 carbon-carbon double bonds.A hydrocarbon group (“C2-10 alkenyl”). In some embodiments, the alkenyl group has 2 to 9 carbon atoms (“C2-9 alkenyl”). In some embodiments, the alkenyl group has 2 to 8 carbon atoms (“C2-8 alkenyl”). In some embodiments, the alkenyl group has 2 to 7 carbon atoms (“C2-7 alkenyl”). In some embodiments, the alkenyl group has 2 to 6 carbon atoms (“C2-6 alkenyl”). In some embodiments, the alkenyl group has 2 to 5 carbon atoms (“C2-5 alkenyl”). In some embodiments, the alkenyl group has 2 to 4 carbon atoms (“C2-4 alkenyl”). In some embodiments, the alkenyl group has 2 to 3 carbon atoms (“C2-3 alkenyl”). In some embodiments, the alkenyl group has 2 carbon atoms (“C2 alkenyl”). The one or more carbon-carbon double bonds can be internal (e.g., in 2-butenyl) or terminal (e.g., in 1-butenyl). Examples of C2-4 alkenyl groups include vinyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), etc. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), etc. Other examples of alkenyl groups include heptenyl (C7), octenyl (C8), octtrienyl (C8), etc.

[0105] "Alkynyl" refers to a straight-chain or branched hydrocarbon group ("C2-10 alkynyl") having 2 to 10 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds). In some embodiments, the alkynyl group has 2 to 9 carbon atoms (“C2-9 alkynyl”). In some embodiments, the alkynyl group has 2 to 8 carbon atoms (“C2-8 alkynyl”). In some embodiments, the alkynyl group has 2 to 7 carbon atoms (“C2-7 alkynyl”). In some embodiments, the alkynyl group has 2 to 6 carbon atoms (“C2-6 alkynyl”). In some embodiments, the alkynyl group has 2 to 5 carbon atoms (“C2-5 alkynyl”). In some embodiments, the alkynyl group has 2 to 4 carbon atoms (“C2-4 alkynyl”). In some embodiments, the alkynyl group has 2 to 3 carbon atoms (“C2-3 alkynyl”). In some embodiments, the alkynyl group has 2 carbon atoms (“C2 alkynyl”). The one or more carbon-carbon triple bonds can be internal (e.g., in 2-butynyl) or terminal (e.g., in 1-butynyl). Examples of C2-4 alkyne groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), and 2-butynyl (C4). Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkyne groups, as well as pentyynyl (C5) and hexynyl (C6). Other examples of alkyne groups include heptyynyl (C7) and octyynyl (C8).

[0106] The terms “haloalkyl” or “lower haloalkyl” or “lower haloalkyl” refer to straight-chain or branched hydrocarbon residues containing 1 to 6 carbon atoms, wherein one or more carbon atoms are substituted by one or more halogen atoms.

[0107] Unless otherwise stated, the terms “alkylene” or “alkaneide” as used herein refer to a divalent saturated straight-chain hydrocarbon group (e.g., (CH2)n) of 1 to 10 carbon atoms or a branched saturated divalent hydrocarbon group (e.g., -CHMe- or -CH2CH(i-Pr)CH2-) of 2 to 10 carbon atoms. Except in the case of methylene, the free valences of alkylenes are not attached to the same atom. Examples of alkylenes include, but are not limited to, methylene, ethylene, propylene, 2-methyl-propylene, 1,1-dimethyl-ethylene, butylene, and 2-ethylbutylene.

[0108] As used herein, the term “alkoxy” means -O-alkyl, wherein the alkyl group is as defined above, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, hexoxy, including their isomers. As used herein, “lower alkoxy” means an alkoxy having a “lower alkyl” as previously defined. As used herein, “C1-10 alkoxy” means -O-alkyl, wherein the alkyl group is C1-10.

[0109] As used herein, the term “hydroxyalkyl” means an alkyl group as defined herein, wherein one to three hydrogen atoms on different carbon atoms are replaced by hydroxyl groups.

[0110] As used herein, the terms “alkylsulfonyl” and “arylsulfonyl” refer to a group of the formula -S(=O)2R, wherein R is either alkyl or aryl, and alkyl and aryl are as defined herein. As used herein, the term “heteroalkylsulfonyl” means a group of the formula -S(=O)2R, wherein R is a “heteroalkyl” as defined herein.

[0111] As used herein, the terms “alkylsulfonylamino” and “arylsulfonylamino” refer to groups of the formula -NR'S(=O)2R, where R is either alkyl or aryl, R' is hydrogen or C1-3 alkyl, and alkyl and aryl are as defined herein.

[0112] As used herein, the term “cycloalkyl” refers to a saturated carbocyclic ring containing 3 to 8 carbon atoms, namely cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. As used herein, “C3-7 cycloalkyl” refers to a cycloalkyl ring consisting of 3 to 7 carbon atoms.

[0113] As used herein, the term carboxyl-alkyl refers to an alkyl moiety in which one hydrogen atom has been replaced by a carboxyl group. It should be understood that the connection point of a heteroalkyl group is through a carbon atom. The term “carboxy” refers to the –CO2H moiety. Specification 21 / 81 pages 35 CN 121358746 A

[0114] As used herein, the term "heteroaryl" or "heteroary group" means a group of 5 to 12 rings having at least one aromatic ring.The heteroaryl group is a monocyclic or bicyclic group, each ring containing four to eight atoms, with one or more N, O, or S heteroatoms incorporated, and the remaining ring atoms being carbon. It should be understood that the heteroaryl group's linkage will be on the aromatic ring. As is well known to those skilled in the art, the aromatic properties of heteroaryl rings are weaker than their all-carbon counterparts. Therefore, for the purposes of this invention, the heteroaryl group only needs to possess a certain degree of aromaticity. Examples of heteroaryl moieties include monocyclic aromatic heterocycles having 5 to 6 ring atoms and 1 to 3 heteroatoms, including but not limited to pyridinyl, pyrimidinyl, pyrazinyl, pyrroleyl, pyrazolyl, imidazolyl, oxazole, isoxazole, thiazole, isothiazole, triazoline, thiadiazole, and oxadiazoline, which may optionally be substituted by one or more, preferably one or two, substituents selected from hydroxyl, cyano, alkyl, alkoxy, thio, lower haloalkoxy, alkylthio, halogen, lower haloalkyl, alkylsulfinyl, alkylsulfonyl, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl and dialkylaminoalkyl, nitro, alkoxycarbonyl and carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, alkylcarbonylamino and arylcarbonylamino. Examples of bicyclic moieties include, but are not limited to, quinolinyl, isoquinolinyl, benzofuranyl, benzobenzylthio, benzoxazole, benzoisoxazole, benzothiazole, and benzoisothiazole. The bicyclic moieties may optionally be substituted on either ring; however, the bonding point is on the ring containing the heteroatom.

[0115] Unless otherwise stated, the terms “heterocyclic group”, “heterocyclic alkyl” or “heterocycle” as used herein refer to a monovalent saturated cyclic group consisting of one or more rings, preferably one or two rings, including spirocyclic systems having three to eight atoms per ring, incorporating one or more cyclic heteroatoms (selected from N, O or S(O)O-2), and optionally independently substituted by one or more, preferably one or two, substituents selected from hydroxyl, oxo, cyano, lower alkyl, lower alkoxy, lower haloalkoxy, alkylthio, halogen, lower haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino. Examples of heterocyclic groups include, but are not limited to, aziridine, pyrrolidinyl, hexahydroaziridine, oxadiazolidinyl, tetrahydrofuranyl, tetrahydrophenylthio, oxazolidinyl, thiazolyl, isoxazolidinyl, morpholinyl, piperazine, piperidinyl, tetrahydropyranyl, thiomorpholinyl, quininecycloyl, and imidazolinyl.

[0116] “Heterocyclic group” or “heterocyclic” refers to a group having a 3- to 14-membered nonaromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3- to 14-membered heterocyclic group”).In a heterocyclic group, the bonding point can be a carbon or nitrogen atom, provided the valence state allows. The heterocyclic group can be monocyclic (“monocyclic heterocyclic group”) or polycyclic (e.g., fused ring, bridged ring, or spirocyclic systems, such as bicyclic systems (“bicyclic heterocyclic group”) or tricyclic systems (“tricyclic heterocyclic group”)), and can be saturated, or may contain one or more carbon-carbon double or triple bonds. A heterocyclic polycyclic system may include one or more heteroatoms in one or two rings. “Hypercyclic group” also includes ring systems in which the heterocyclic ring as defined above is fused with one or more carbocyclic groups, wherein the bonding point is on the carbocyclic or heterocyclic ring; or ring systems in which the heterocyclic ring as defined above is fused with one or more aryl or heteroaryl groups, wherein the bonding point is on the heterocyclic ring, and in such cases, the number of ring members still refers to the number of ring members in the heterocyclic ring system.

[0117] In some embodiments, the heterocyclic group is a 5-10 membered non-aromatic ring system having a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heterocyclic group”). In some embodiments, the heterocyclic group is a 5-8 membered non-aromatic ring system having a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclic group”). In some embodiments, the heterocyclic group is a 5-6 membered non-aromatic ring system having a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclic group”). In some embodiments, the 5-6 membered heterocyclic group has 1-3 cyclic heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclic group has 1-2 cyclic heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclic group has one cyclic heteroatom selected from nitrogen, oxygen, and sulfur. Specification 22 / 81 pages 36 CN 121358746 A

[0118] Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to, aziridinyl, oxetaneyl, and thiopyraneyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to, aziridaneyl, oxetaneyl, and thiopyraneyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrophenylthio, dihydrophenylthio, pyrrolyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxopentyl, oxothiopentanyl, and dithiopentanyl. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary six-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thiaalkyl. Exemplary six-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithiaalkyl, and dioxalyl. Exemplary six-membered heterocyclic groups containing three heteroatoms include...Exemplary 6-membered heterocyclic groups include, but are not limited to, triazine alkyl groups. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azirheptanyl, oxetaneheptyl, and thioheptanyl. Exemplary 8-membered heterocyclic groups containing one heteroatom include, but are not limited to, azirheptanyl, oxetaneheptyl, and thioheptanyl. Exemplary bicyclic heterocyclic groups include, but are not limited to, indololinyl, isoindololinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, tetrahydrobenzothiophenyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthidyl, decahydro-1,8-naphthidyl, octahydropyrrolo[3,2-b]pyrrole, indololinyl, phthalimide, naphthalimide, chromenyl, 1H-benzo[e][1,4]diazazonyl, 1,4,5,7-Tetrahydropyrano[3,4-b]pyrrole, 5,6-dihydro-4H-furano[3,2-b]pyrrole, 6,7-dihydro-5H-furano[3,2-b]pyrrole, 5,7-dihydro-4H-thieno[2,3-c]pyrrole, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridyl, 2,3-dihydrofurano[2,3-b]pyridyl, 4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridyl, 4,5,6,7-tetrahydrofurano[3,2-c]pyridyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridyl, 1,2,3,4-tetrahydro-1,6-naphthidyl, etc.

[0119] "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., a ring array with 6, 10, or 14 π electrons) having 6-14 ring carbon atoms and no heteroatoms in the aromatic ring system ("C6-14 aryl"). In some embodiments, the aryl has 6 ring carbon atoms ("C6 aryl"; for example, phenyl). In some embodiments, the aryl has 10 ring carbon atoms ("C10 aryl"; for example, naphthyl, such as 1-naphthyl (α-naphthyl) and 2-naphthyl (β-naphthyl)). In some embodiments, the aryl has 14 ring carbon atoms ("C14 aryl"; for example, anthracene). "Aryl" also includes a ring system in which the aryl ring as defined above is fused with one or more carbocyclic or heterocyclic groups, wherein the linking group or linking point is on the aryl ring, and in such cases, the number of carbon atoms still refers to the number of carbon atoms in the aryl ring system.

[0120] "Heteroaryl" refers to a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., a ring array with 6, 10, or 14 π electrons in total), having a cyclic carbon atom and providing 1-4 cyclic heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-14 membered heteroaryl"). In the presence of one or more nitrogen atoms...In heteroaryl groups, the linkage can be a carbon or nitrogen atom, provided the valence state allows. A heteroaryl polycyclic system can include one or more heteroatoms in one or two rings. "Hyperaryl" includes a ring system in which a heteroaryl ring as defined above is fused with one or more carbocyclic or heterocyclic groups, wherein the linkage is on the heteroaryl ring, and in such cases, the number of ring members still refers to the number of ring members in the heteroaryl ring system. "Hyperaryl" also includes a ring system in which a heteroaryl ring as defined above is fused with one or more aryl groups, wherein the linkage is on the aryl or heteroaryl ring, and in such cases, the number of ring members still refers to the number of ring members in the fused polycyclic (aryl / heteraryl) ring system. In a polycyclic heteroaryl group (e.g., indolyl, quinolinyl, carbazolyl, etc.) where one ring does not contain a heteroatom, the linkage can be on either ring, i.e., a ring with a heteroatom (e.g., 2-indolyl) or a ring without a heteroatom (e.g., 5-indolyl).

[0121] In some embodiments, the heteroaryl group is a 5-10 cyclic aromatic ring system having a cyclic carbon atom and providing 1-4 cyclic heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 cyclic heteroaryl”). In some embodiments, the heteroaryl group is a 5-8 cyclic aromatic ring system having a cyclic carbon atom and providing 1-4 cyclic heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 cyclic heteroaryl”). In some embodiments, the heteroaryl group is a 5-6 cyclic aromatic ring system having a cyclic carbon atom and providing 1-4 cyclic heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 cyclic heteroaryl”). In some embodiments, the 5-6 cyclic heteroaryl group has 1-3 cyclic heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl group has 1-2 cyclic heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl group has 1 cyclic heteroatom selected from nitrogen, oxygen, and sulfur.

[0122] Exemplary 5-membered heteroaryl groups containing 1 heteroatom include, but are not limited to, pyrroleyl, furanyl, and phenylthioyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing 1 heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include, but are not limited to, pyridinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, but are not limited to, triazinyl and tetraazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, aziridine, oxaziridine, and thioaziridine. Example 5,6-Bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazole, benzotriazolyl, benzobenzylthio, isobenzobenzylthio, benzofuranyl, benzoisofuranyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, indolazinyl, and purinel. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthidyl, pteridyl, quinolinyl, isoquinolinyl, cenolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, but are not limited to, phenanthridine, dibenzofuranyl, carbazole, acridineyl, phenothiazinyl, phenotoxazinyl, and phenothiazinyl.

[0123] "Saturated" refers to a ring portion that does not contain double or triple bonds, i.e., the ring contains only single bonds.

[0124] Alkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups may optionally be substituted. Optional substitution refers to groups that can be substituted or are not substituted. Generally, the term "substituted" means that at least one hydrogen atom present on the group is replaced by a non-hydrogen substituent, and the substitution results in a stable compound, such as a compound that does not spontaneously undergo transformation such as through rearrangement, cyclization, elimination, or other reactions. Heteroatoms such as nitrogen, oxygen, and sulfur may have hydrogen substituents and / or non-hydrogen substituents that satisfy the heteroatom's valence state and lead to the formation of a stable compound.

[0125] As used herein, an exemplary non-hydrogen substituent where a portion is “optionally substituted” means that the portion may be substituted by any other portion selected from, but not limited to, the following: halogen, –CN, –NO2, –N3, –SO2H, –SO3H, –OH, –OR aa, –N(Rbb)2, –N(OR cc)Rbb, –SH, –SRaa, –C(=O)Raa, –CO2H, –CHO, –CO2Raa, –OC(=O)Raa, –OCO2Raa, –C(=O)N(Rbb)2, –OC(=O)N(Rbb)2, –NR bbC(=O)Raa, –NRbbCO2Raa, –NRbbC(=O)N(Rbb)2, –C(=NR bb)Raa, –C(= NRbb)ORaa, –OC(=NRbb)Raa, –OC(=NRbb)ORaa, –C(=NRbb)N(Rbb)2, –OC(=NR bb)N(Rbb)2, –NR bbC(= NRbb)N(Rbb)2, –C(=O)NR bbSO2R aa, –NRbbSO2R aa, –SO2N(R bb)2, –SO2R aa, –S(=O)Raa, –OS(=O)Raa, –B (ORcc)2, C1–10 alkyl, C2–10 alkenyl, C2–10 alkynyl, C3–14 carbocyclic, 3 to 14 membered heterocyclic, C6–14 aryl and 5 to 14 membered heterocyclicAryl group, wherein each alkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently substituted by 0, 1, 2, 3, 4, or 5 Rdd groups, or the two hydrogen atoms on the carbon atom are replaced by the =O group; each Raa group is independently selected from C1–10 alkyl, C1–10 perhaloalkyl, C2–10 alkenyl, C2–10 ynyl, C3–14 carbocyclic, 3 to 14-membered heterocyclic, C6–14 aryl, and 5 to 14-membered heteroaryl, or two Raa groups are linked to form a 3 to 14-membered heterocyclic or 5 to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently substituted by 0, 1, 2, 3, 4, or 5 Rdd groups; each Rbb group is independently selected from hydrogen, –OH, –ORaa, –N(Rcc)2, –CN, –C(=O)R aa, –C(=O)N(Rcc)2, –CO2R aa, –SO2R aa, –SO2N (Rcc)2, –SOR aa, C1–10 alkyl, C1–10 perhaloalkyl, C2–10 alkenyl, C2–10 ynyl, C3–14 carbocyclic, 3 to 14 membered heterocyclic, C6–14 aryl and 5 to 14 membered heteroaryl, or two Rbb groups linked to form a 3 to 14 membered heterocyclic or 5 to 14 membered heteroaryl ring, wherein each alkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl and heteroaryl group is independently bounded by 0, 1, 2, 3, 4 or 5 Rdd groups. Group substitution; each Rcc group is independently selected from hydrogen, C1–10 alkyl, C1–10 perhaloalkyl, C2–10 alkenyl, C2–10 ynyl, C3–14 carbocyclic, 3 to 14-membered heterocyclic, C6–14 aryl, and 5 to 14-membered heteroaryl, or two Rcc groups are linked to form a 3 to 14-membered heterocyclic or 5 to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently substituted by 0, 1, 2, 3, 4, or 5 Rdd groups; and each Rdd group is independently selected from halogen, –CN, –NO2, –N3, –SO2H, –SO3H, –OH, –OC1–6 alkyl, –ON(C1–6 alkyl)2, –N(C1–6 alkyl)2, –N(OC1–6 alkyl)(C1–6 alkyl), –N (OH)(C1–6 alkyl), –NH(OH), –SH, –SC1–6 alkyl, –C(=O)(C1–6 alkyl), –CO2H, –CO2(C1–6 alkyl), –OC(=O)(C1–6 alkyl), –OCO2(C1–6 alkyl), –C(=O)NH2, –C(=O)N(C1–6 alkyl)2, –OC(=O)NH(C1–6 alkyl), –NHC (=O)(C1–6 alkyl), –N(C1–6 alkyl)C(=O)(C1–6 alkyl), –NHCO2(C1–6 alkyl), –NHC(=O)N(C1–6 alkyl)2, –NHC(=O)NH(C1–6 alkyl), –NHC(=O)NH2, –C(=NH)O(C1–6 alkyl), –OC(=NH)(C1–6 alkyl), –OC(=NH)OC1–6 alkyl, –C(=NH)N(C1–6 alkyl)2, –C(=NH)NH(C1–6 alkyl), –C(=NH)NH2, –OC(=NH)N(C1–6 alkyl)2, –OC(NH)NH(C1–6 alkyl), –OC(NH)NH2, –NHC(NH)N(C1–6 alkyl)2, –NHC(=NH)NH2, –NHSO2(C1–6 alkyl) Alkyl), –SO2N(C1–6 alkyl)2, –SO2NH(C1–6 alkyl), –SO2NH2, –SO2C1–6 alkyl, –B(OH)2, –B(C1–6 alkyl)2, C1–6 alkyl, C1–6 perhaloalkyl, C2–6 alkenyl, C2–6 alkynyl, C3–10 carbocyclic, C6–10 aryl, 3 to 10-membered heterocyclic and 5 to 10-membered heteroaryl; or two Rdd substituents on the carbon atom may be linked to form =O.

[0126] “Halogen” or “halogen” means fluorine (fluorinated, –F), chlorine (chlorinated, –Cl), bromine (brominated, –Br) or iodine (iodinated, –I).

[0127] As used herein, the term “composition” is intended to cover products comprising the specified ingredients and any products directly or indirectly produced by combinations of the specified ingredients.

[0128] “Salt” includes any and all salts. "Pharmaceutically acceptable salts" are those salts that, within reasonable medical judgment, are suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reactions, etc., and whose benefits are proportionate to a reasonable risk-benefit ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. described pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1–19. Pharmaceutically acceptable salts include salts derived from inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts include salts formed by amino groups with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by other methods employed in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipic acid salts, alginate salts, ascorbate salts, aspartate salts, benzenesulfonate salts, benzoate salts, hydrogen sulfate salts, borate salts, butyrate salts, camphorate salts, camphorsulfonate salts, citrate salts, cyclopentanepropionate salts, diglucuronide salts, dodecyl sulfate salts, ethanesulfonate salts, formate salts, fumarate salts, glucoheponic acid salts, glycerol phosphate salts, glucuronide salts, and hemisulfate salts.Heptanoates, hexanoates, hydroiodates, 2-hydroxy-ethanesulfonates, lacturonates, lactates, laurates, lauryl sulfates, malates, maleates, malonates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oleates, oxalates, palmitates, dihydroxynaphthalates, pectates, persulfates, 3-phenylpropionates, phosphates, picrates, neopentanoates, propionates, stearates, succinates, sulfates, tartrates, thiocyanates, p-toluenesulfonates, undecanoates, valerates, etc. Pharmaceutically acceptable salts derived from suitable bases include alkali metal salts, alkaline earth metal salts, ammonium salts, and N+(C1–4 alkyl)4 salts. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium. Further pharmaceutically acceptable salts include non-toxic ammonium salts, quaternary ammonium salts, and amine cation salts formed, where appropriate, using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0129] Unless otherwise stated, the compounds described herein may contain one or more asymmetric centers and thus may exist in a variety of stereoisomeric forms, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of a single enantiomer, diastereomer, or geometric isomer, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched with one or more stereoisomers. Isomers can be separated from mixtures by methods known to those skilled in the art, including chiral high-performance liquid chromatography (HPLC). The compounds described herein may be in the form of a single isomer and substantially free of other isomers, or in the form of a mixture of various isomers.

[0130] Unless otherwise stated, the structures described herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the structure of the present invention but with hydrogen replaced by deuterium or tritium, 19F replaced by 18F, carbon enriched by 13C- or 14C-, and / or oxygen atoms replaced by 18O are within the scope of this disclosure. Other examples of isotopes include 15N, 18O, 17O, 31P, 32P, 35S, 18F, 36Cl, and 123I. Compounds having such isotopically enriched atoms can be used as analytical tools or probes, for example, in bioassays.

[0131] Certain isotopically labeled compounds (e.g., compounds labeled with 3H and 14C) can be used for the determination of the tissue distribution of compounds and / or substrates. Tritium (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred due to their ease of preparation and detectability.

[0132] Certain isotope-labeled compounds of formula (I) can be used for medical imaging purposes, for example, by using positron emission tomography (PET) to positron-labeled compounds.Compounds labeled with isotopes such as 11C or 18F can be used in positron emission tomography (PET) applications, and compounds labeled with gamma-ray emitting isotopes such as 123I can be used in single-photon emission computed tomography (SPECT) applications. Furthermore, substitution with heavier isotopes such as deuterium (i.e., 2H) can offer certain therapeutic advantages due to greater metabolic stability (e.g., increased in vivo half-life or reduced dose requirement), and is therefore preferred in some cases. Additionally, isotopic substitution at the site of epimerization can slow down or weaken the epimerization process, thereby maintaining a more active or potent form of the compound for a longer period. Isotopically labeled compounds of formula (I), particularly those containing isotopes with long half-lives (t1 / 2 > 1 day), can typically be prepared by replacing non-isotopically labeled reagents with appropriate isotopically labeled reagents according to a procedure similar to that disclosed in the schemes and / or examples herein.

[0133] If there is a discrepancy between the depicted structure and the name given to that structure, the depicted structure shall prevail. Additionally, if the stereochemistry of a structure or part thereof is not indicated, for example, in bold or dashed, the structure or part thereof shall be interpreted to encompass all its stereoisomers. However, in some cases where more than one chiral center is present, the structure and name may be represented as a single enantiomer to aid in describing the relative stereochemistry. Those skilled in the art of organic synthesis will know from the methods used to prepare the compound whether it is prepared as a single enantiomer.

[0134] Table 1. In the various embodiments described herein, dengue inhibitors of any of formulas I-V or their pharmaceutically acceptable salts and / or stereoisomers are selected from one of the compounds shown in Table 1 below. Instruction Manual 26 / 81 Page 40 CN 121358746 A Instruction Manual 27 / 81 Page 41 CN 121358746 A Instruction Manual 28 / 81 Page 42 CN 121358746 A Instruction Manual 29 / 81 Page 43 CN 121358746 A Instruction Manual 30 / 81 Page 44 CN 121358746 A Instruction Manual 31 / 81 Page 45 CN 121358746 A Instruction Manual 32 / 81 Page 46 CN 121358746 A Instruction Manual 33 / 81 Page 47 CN 121358746 A Instruction Manual 34 / 81 Page 48 CN 121358746 A Instruction Manual 35 / 81 Page 49 CN121358746 A Instruction Manual 36 / 81 Page 50 CN 121358746 A

[0135] Common abbreviations in the examples Commonly used abbreviations include: acetyl (Ac), azobisisobutyronitrile (AIBN), atmospheric pressure (Atm), 9-boronbicyclo[3.3.1]nonane (9-BBN or BBN), tert-butyloxycarbonyl (Boc), ditert-butyl pyrocarbonate or boc anhydride (BOC2O), benzyl (Bn), butyl (Bu), Chemical Abstracts Service Registry Number (CASRN), benzyloxycarbonyl (CBZ or Z), carbonyl diimidazole (CDI), 1,4-diazabicyclo[2.2.2]octane (DABCO), diethylaminosulfur trifluoride (DAST), dibenzylacetone (dba), 1,5-diazabicyclo[4.3.0]non-5-ene ( DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N,N'-dicyclohexylcarbodiimide (DCC), 1,2-dichloroethane (DCE), dichloromethane (DCM), diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), diisobutylaluminum hydride (DIBAL or DIBAL-H), 1,3-diisopropylcarbodiimide (DIC), diisopropylethylamine (DIPEA), N,N-dimethylacetamide (DMA), 4-N,N-dimethylaminopyridine (DMAP), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,1 '-Bis-(diphenylphosphino)ethane (dppe), 1,1'-bis-(diphenylphosphino)ferrocene (dppf), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), ethyl (Et), ethyl acetate (EtOAc), ethanol (EtOH), ethyl 2-ethoxy-2H-quinoline-1-carboxylate (EEDQ), diethyl ether (Et2O), O-(7-azabenzotriazol-1-yl)-N,N,N'N'-tetramethylureonium hexafluorophosphate acetic acid (HATU), acetic acid (HOAc), 1-N-hydroxybenzotriazole (HOBt), high-performance liquid chromatography (HPLC), isopropanol (IPA), lithium hexamethyldisilazane (LiHMDS), methanol (MeOH), melting point (mp), MeSO2- (Methanesulfonyl or Ms), Methyl (Me), Acetonitrile (MeCN), m-chloroperoxybenzoic acid (MCPBA), Mass spectrometry (ms), Methyl tert-butyl ether (MTBE), N-bromosuccinimide (NBS), N-carboxylic anhydride (NCA), N-chlorosuccinimide (NCS), N-methylmorpholine (NMM), N-methylpyrrolidone (NMP), Pyridinium chlorochromate (PCC), DichromiumPyridinium acid (PDC), phenyl (Ph), propyl (Pr), isopropyl (i-Pr), psi, pyridine (pyr), room temperature (rt or RT), tert-butyldimethylsilyl or t-BuMe2Si (TBDMS), triethylamine (TEA or Et3N), 2,2,6,6-tetramethylpiperidin-1-oxy (TEMPO), trifluoromethanesulfonate or CF3SO2- (Tf), trifluoroacetic acid (TFA), 1,1'-bis-2,2,6,6-tetramethylheptane-2,6-dione (TMHD), O-benzotriazol-1-yl-N,N,N',N'-tetramethylurea-tetrafluoroborate (TBTU), thin-layer chromatography (TLC), tetrahydrofuran (THF), trimethylsilyl or Me3Si (TMS), p-toluenesulfonic acid monohydrate (TsOH or pTsOH), 4-Me-C6H4SO2- or toluenesulfonyl (Ts), N-urethane-N-carboxylic anhydride (UNCA). Conventional nomenclature, including prefixes such as n, i-, sec-, tert-, and neo, has its usual meaning when used with alkyl moiety. (J. Rigaudy and D. P. Klesney, Nomenclature in Organics, 37 / 81 pages, 51 CN 121358746 A Chemistry, IUPAC 1979 Pergamon Press, Oxford.)

[0136] Example 1 Synthesis of Compound 1 Synthesis scheme: Step 1: Synthesis of N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide: TMSCl (2.57 mL, 20.3 mmol) was added dropwise to a stirred solution of (2R,3R,4S,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (1.2 g, 4.51 mmol) in anhydrous pyridine (10 mL) at 0 °C, and the resulting reaction mixture was stirred at the same temperature for 30 min. Then benzoyl chloride (848 µL, 6.76 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 16 h. After the reaction was complete, it was quenched with water (0.7 mL), followed by 1.8 mL of 25% NH4OH aqueous solution, and the resulting mixture was stirred for another 10 minutes. The solvent was removed under vacuum, the residue was diluted with water (20 mL), and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, and the filtrate was concentrated under vacuum to give the crude product (1.7 g).

[0137] TBAF (2.5 mL, 9.12 mmol) was added to a solution of the crude product in anhydrous THF (15 mL) at 0 °C. The resulting reaction mixture was stirred at room temperature for 1 h. After the reaction was complete, the solvent was removed under vacuum. The residue was purified by silica gel column chromatography using 5–8% MeOH in DCM as the eluent to give N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3d]pyrimidin-4-yl)benzamide (700 mg, 50%) as a white solid. LCMS (ESI): m / z 371.05 [M+H]+.

[0138] Step 2: Synthesis of N-(7-((2R,3R,4S,5S)-3,4-dihydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide: A solution of I2 (905 mg, 3.56 mmol) in THF (2 ml) was added to a stirred solution of N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (0.6 g, 1.62 mmol), PPh3 (1.19 g, 4.54 mmol) and 1H-imidazolium (309 mg, 4.54 mmol) in anhydrous THF (8 mL). The reaction mixture was stirred at room temperature for 16 h. After the reaction was complete, the mixture was quenched with saturated sodium thiosulfate aqueous solution (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography using 5% MeOH in DCM as eluent to give N-(7-((2R,3R,4S,5S)-3,4-dihydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (0.6 g, 77%) as a grayish-white solid. LCMS (ESI): m / z 481.00 [M+H]+.

[0139] Step 3: Synthesis of N-(7-((2R,3R,4S)-3,4-dihydroxy-5-methylenetetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide: At room temperature, N-(7-((2R,3R,4S,5S)-3,4-dihydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (590 mg, 1.23 mmol) was added to anhydrous THF.1,8-diazabicyclo[5.4.0]undec-7-ene (275 µL, 1.84 mmol) was added to the stirred solution (8 mL). The reaction mixture was stirred at 50 °C for 2 h. After the reaction was complete, the solvent was removed under vacuum, and the residue was purified by silica gel column chromatography using 3-5% MeOH eluent in DCM to give N-(7-((2R,3R,4S)-3,4-dihydroxy-5-methylenetetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (250 mg, 58%) as a grayish-white solid. LCMS (ESI): m / z 353.00 [M+H]+.

[0140] Step 4: Synthesis of N-(7-((2R,3R,4S,5R)-5-fluoro-3,4-dihydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide: TEA·3HF (139 µL, 0.851 mmol) was added to a stirred solution of (7-((2R,3R,4S)-3,4-dihydroxy-5-methylenetetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (250 mg, 0.710 mmol) in anhydrous ACN (12 mL) at 0 °C. Then, a solution of NIS (192 mg, 0.851 mmol) in ACN (3 mL) was added, and the resulting reaction mixture was stirred at 0 °C for 40 min. The reaction system was heated to room temperature and stirred for another 40 minutes to form a solid precipitate. After the reaction was complete, the precipitate was filtered and washed with ACN to obtain N-(7-((2R,3R,4S,5R)-5-fluoro-3,4-dihydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (200 mg, 57%), as a white solid. LCMS (ESI): m / z 498.75 [M+H]+.

[0141] Step 5: Synthesis of (2R,3S,4R,5R)-5-(4-benzoamide-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(iodomethyl)tetrahydrofuran-3,4-dimethylbenzyl ester: Benzoic anhydride (216 mg, 0.953 mmol) and DMAP (9.39 mg, 0.076 mmol) were added to a stirred solution of N-(7-((2R,3R,4S,5R)-5-fluoro-3,4-dihydroxy-5-(iodomethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (190 mg, 0.381 mmol) in anhydrous ACN (5 mL) at 0 °C. The reaction mixture was stirred at room temperature for 6 h. After the reaction was complete, the mixture was...EtOAc (15 mL) was diluted and washed with water (15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography using 10–40% EtOAc in heptane as the eluent to give (2R,3S,4R,5R)-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(iodomethyl)tetrahydrofuran-3,4-dimethylbenzoate (180 mg, 67%) as a grayish-white solid. LCMS (ESI): m / z 706.80 [M+H]+.

[0142] Step 6: Synthesis of (2S,3S,4R,5R)-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-((benzoyloxy)methyl)-2-fluorotetrahydrofuran-3,4-dimethyldibenzoate: Sodium benzoate (277 mg, 1.93 mmol) was added to a stirred solution of (2R,3S,4R,5R)-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(iodomethyl)tetrahydrofuran-3,4-dimethyldibenzoate (170 mg, 0.241 mmol) in DMF (17 mL) at room temperature. The reaction system was stirred at 120 °C for 16 h. After the reaction was complete, the mixture was diluted with EtOAc (20 mL) and washed with ice-cold water (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography using 20–50% EtOAc in heptane as the eluent to give (2S,3S,4R,5R)-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(benzoyloxy)methyl)-2-fluorotetrahydrofuran-3,4-dimethylbenzoate (130 mg, 77%) as a white solid. LCMS (ESI): m / z 700.95 [M+H]+.

[0143] Step 7: Synthesis of (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol (1): A solution of (2S,3S,4R,5R)-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-((benzoyloxy)methyl)-2-fluorotetrahydrofuran-3,4-dimethyl dibenzoate (40 mg, 0.057 mmol) in methylamine (33% in ethanol, 2 mL) was stirred at room temperature for 16 h. After the reaction was complete, the reaction mixture was concentrated under vacuum at low temperature. 5% of the solution in DCM was used.The residue was purified by grinding in MeOH to obtain (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol (4.5 mg, 28%), as a grayish-white solid. 1H‑NMR (400 MHz, DMSO‑d 6): δ 8.07 (s, 1H) , 7.26 (d , J = 3.6, 1H) , 7.08 (s, 2H) , 6.61 (d , J = 3.6 Hz, 1H) , 6.33 (d , J = 3.2 Hz, 1H), 5.66 (d, J = 5.6 Hz, 1H), 5.38 (t, J = 6.4 Hz, 1H), 5.16 (d, J = 8.8 Hz, 1H), 4.52-4.44 (m, 1H), 4.38-4.34 (m, 1H) , 3.54 (t, J = 6.4 Hz, 2H). LCMS(ESI): m / z 285.15 [M+H]+.

[0144] Compounds 6, 10, 11, 12, 14-18, 21-26, 28, 31, 33, 35-45, 50, 52-55 and 72 were synthesized using a procedure similar to that used for synthesizing compound 1.

[0145] Example 2 Synthesis step 1 of compound 2: Synthesis of (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-2-(iodomethyl)tetrahydrofuran-3,4-diol: Sodium azide (576 mg, 8.86 mmol) was added to a stirred solution of iodine monochloride (654 mg, 4.03 mmol) in anhydrous DMF (4 mL) at 0 °C. The resulting mixture was stirred at room temperature for 30 minutes. The reaction mixture was cooled again to 0°C, and a solution of (2R,3R,4S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-methylenetetrahydrofuran-3,4-diol (0.4 g, 1.61 mmol) in anhydrous DMF (2 mL) was added dropwise. The reaction mixture was stirred further at room temperature for 2 h. After the reaction was complete, the reaction was quenched with a saturated aqueous sodium thiosulfate solution (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography using 0–10% MeOH in DCM as the eluent to give (2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-2-(iodomethyl)tetrahydrofuran-3,4-diol (105 mg, 16%) is a yellow, viscous gel. LCMS (ESI): m / z 417.85 [M+H]+.

[0146] Step 2: Synthesis of (2S,3S,4R,5R)-2-azido-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(iodomethyl)tetrahydrofuran-3,4-dimethyl dibenzoate: Benzoyl chloride (163 µL, 1.4 mmol) was added to a stirred solution of (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-2-(iodomethyl)tetrahydrofuran-3,4-diol (130 mg, 0.312 mmol) and DMAP (11.4 mg, 0.093 mmol) in anhydrous pyridine (2.6 mL) at 0 °C. The resulting mixture was stirred at room temperature for 1 h. After the reaction was complete, the reaction system was diluted with 10% sodium bicarbonate aqueous solution (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography using 30-50% EtOAc in heptane as the eluent to give (2S,3S,4R,5R)-2-azido-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(iodomethyl)tetrahydrofuran-3,4-dimethylbenzoate (110 mg, 48%) as a white solid. LCMS (ESI): m / z 728.09 [M-H]-.

[0147] Step 3: Synthesis of (2R,3S,4R,5R)-2-azido-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-dimethyldibenzoate: The pH of Bu4NOH (55%) (6 mL) was adjusted to 4 by adding TFA (approximately 1.2 mL). The resulting buffer solution (2 mL) was added at 0 °C to a stirred solution of (2S,3S,4R,5R)-2-azido-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(iodomethyl)tetrahydrofuran-3,4-dimethyldibenzoate (105 mg, 0.144 mmol) in anhydrous DCM (2 mL). mCPBA (149 mg, 0.864 mmol) was added in portions under vigorous stirring. The reaction mixture was stirred at room temperature for 16 h. After the reaction was complete, the mixture was treated with DCM (10...The solution was diluted (mL) and washed with a saturated aqueous sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography using 10–60% EtOAc in heptane as the eluent to give (2R,3S,4R,5R)-2-azido-5-(4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-dimethylbenzoate (50 mg, 56%) as a white solid. LCMS (ESI): m / z 620.1 [M+H]+.

[0148] Step 4: Synthesis of (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol (2): A solution of (2R,3R,4S,5R)-5-azido-2-{4-benzoylamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-4-(benzoyloxy)-5-(hydroxymethyl)oxacyclopentane-3-ylbenzoate (50 mg, 0.080 mmol) in NH3 (7M in MeOH, 1 mL) was stirred at room temperature for 16 h. After the reaction was complete, the mixture was concentrated under vacuum. The residue was purified by reversed-phase preparative HPLC to obtain the desired (2R,3S,4R,5R)-5-{4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-azido-2-(hydroxymethyl)oxacyclopentane-3,4-diol (4.5 mg, 18%), as a white solid. 1H‑NMR (400 MHz, DMSO‑d 6, D2O at HT): δ 8.06 (s, 1H) , 7.29 (d , J = 3.6, 1H) , 6.62 (d , J = 3.2 Hz, 1H) , 6.25 (d , J = 6 Hz, 1H) , 4.61 (t, J = 6.4 Hz, 1H), 4.33 (d, J = 5.6 Hz, 1H), 3.56 (d, J = 12 Hz, 1H), 3.46 (d, J = 11.6 Hz, 1H). LCMS (ESI): m / z 308.2 [M+H]+.

[0149] Compounds 7, 8, and 9 were synthesized using a procedure similar to that used for synthesizing compound 2.

[0150] Example 3 Synthesis specification of compound 3 41 / 81 pages 55 CN 121358746 A Step 1: (3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-3,4-bis(benzyloxy)Synthesis of 5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-ol: Chloro[2-(chlorodimethylsilyl)ethyl]dimethylsilane (16.42 g, 76.298 mmol) was added to a stirred solution of 7-bromopyrrolo[2,1-f][1,2,4]triazine-4-amine (16.25 g, 76.298 mmol) in THF (380 mL), and the resulting reaction mixture was stirred at 0 °C under a nitrogen atmosphere for 10 min, followed by dropwise addition of 2,2,6,6-tetramethylpiperidine (10.78 g, 76.298 mmol) at the same temperature. The reaction mixture was stirred at 0 °C for 30 min, and then cooled to -78 °C. A solution of n-BuLi (240 mL, 1.6 M in hexane) was added dropwise over 30 min. The reaction mixture was stirred at -78 °C under a nitrogen atmosphere for 1 h. A solution of (3R,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxacyclopentan-2-one (30 g, 69.362 mmol) in THF (100 mL) was added dropwise to the above mixture at -78 °C over 5 minutes. The resulting reaction mixture was stirred at -78 °C for another 2 h. The reaction was quenched with a saturated aqueous solution of NH4Cl at -78 °C. The resulting mixture was extracted with EtOAc (3 x 500 mL). The combined organic layers were washed with brine (1 x 30 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography after elution with PE / THF (2:1) to give (3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-ol, as a yellow oil (24.0 g, 61%). LCMS (ESI): m / z 589.3 [M+H]+.

[0151] Step 2: Synthesis of 7-((2S,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)pyrrolo[2,1-f][1,2,4]triazine-4-amine: Add Et3SiH (18.06 g, 155.296 mmol) to a stirred solution of (3R,4R,5R)-2-{4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl}-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxacyclopentan-2-ol (22 g, 38.824 mmol) in DCM (200 mL).The resulting mixture was stirred at 0 °C under a nitrogen atmosphere for 5 minutes, followed by the dropwise addition of BF3·Et2O (5.27 g, 77.648 mmol) at 0 °C. The reaction system was stirred at room temperature under a nitrogen atmosphere for 1 h. After the reaction was complete, the reaction was quenched with a saturated NH4Cl aqueous solution at 0 °C. The resulting mixture was extracted with EtOAc (3 x 500 mL). The combined organic layers were washed with brine (1 x 30 mL) and dried over anhydrous sodium sulfate. The residue was purified by silica gel column chromatography after elution with PE / THF (2:1) to give 7-((2S,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)pyrrolo[2,1-f][1,2,4]triazine-4-amine as a yellow oil (21.0 g, 98%). LCMS (ESI): m / z 551.3 [M+H]+.

[0152] Step 3: Synthesis of (2S,3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol: Boron trichloride (17.02 g, 145.3 mmol) was added to a stirred solution of 7-[(2S,3S,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxacyclopentan-2-yl]pyrrolo[2,1-f][1,2,4]triazine-4-amine (8 g, 14.528 mmol) in DCM (100 mL), and the resulting reaction mixture was stirred at 0 °C under a nitrogen atmosphere for 3 minutes. The reaction system was stirred for 30 minutes at room temperature under a nitrogen atmosphere. After the reaction was complete, the reaction was quenched at 0°C with saturated sodium bicarbonate aqueous solution (50 mL). The resulting mixture was separated using a separatory funnel. The aqueous phase was purified by reversed-phase rapid chromatography. The fraction was lyophilized and then further purified by preparative chiral SFC to give (2S,3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol (1.56 g, 38%) (main peak in SFC). 1H NMR (400 MHz, DMSO‑d6) δ 7.82 (s, 1H) , 7.64 (s, 2H) , 6.84 (d , J = 4.4 Hz, 1H) , 6.70 (d , J = 4.4 Hz, 1H) , 5.39 (s, 1H) , 3.78‑ 3.73 (m, 2H) , 3.69 (d , J = 8.0 Hz, 1H) , 3.61-3.57 (m, 1H) , 0.79 (s, 3H). LCMS(ESI): m / z 281.2 [M+H]+.

[0153] Step 4: Synthesis of (2S,3R,4R,5S)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-(iodomethyl)-3-methyltetrahydrofuran-3,4-diol: A solution of (2S,3R,4R,5R)-2-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-(hydroxymethyl)-3-methyloxacyclopentane-3,4-diol (1.51 g, 5.387 mmol) in THF (80 mL) was treated at room temperature with triphenylphosphine (3.53 g, 13.458 mmol), imidazole (526 mg, 7.726 mmol) and pyridine (3.0 mL, 37.28 mmol). A solution of iodine (2.73 g, 10.774 mmol) in THF (5 mL) was added dropwise to the above mixture over 15 minutes at 0 °C, and the resulting mixture was stirred at room temperature for 4 h. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography after elution with DCM / MeOH (10:1) to give (2S,3R,4R,5S)-2-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-(iodomethyl)-3-methyloxacyclopentane-3,4-diol (1.77 g, 84%) as a brown solid. LCMS (ESI): m / z 391.0 [M+H]+.

[0154] Step 5: Synthesis of (2S,3R,4S)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3-methyl-5-methylenetetrahydrofuran-3,4-diol: Sodium methoxide (1.77 mL, 9.558 mmol) was added dropwise to a stirred solution of (2S,3R,4R,5S)-2-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-(iodomethyl)-3-methyloxacyclopentane-3,4-diol (1.77 g, 4.537 mmol) in THF (20 mL), and the resulting reaction mixture was stirred at 60 °C for 2 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 10 mL) and dried over anhydrous sodium sulfate. The solvent was removed under vacuum, and the residue was eluted with DCM / MeOH (10:1). The residue was purified by silica gel column chromatography to give (2S,3R,4S)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-3-methyl-5-methylenetetrahydrofuran-3,4-diol (480.0 mg, 40%) as a yellow oil. LCMS (ESI): m / z 263.3[M+H]+. Instructions 43 / 81 pages 57 CN 121358746 A

[0155] Step 6: Synthesis of (2S,3S,4R)-2-(4-acetamidopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3-methyl-5-methylenetetrahydrofuran-3,4-dimethyldiacetate: Ac2O (934.21 mg, 9.150 mmol) was added to a stirred solution of (2S,3R,4S)-2-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-3-methyl-5-methyleneoxacyclopentane-3,4-diol (400 mg, 1.525 mmol) in anhydrous pyridine (5 mL) at 0 °C. The reaction system was stirred at room temperature for 6 h. After the reaction was complete, the reaction mixture was diluted with EtOAc (15 mL) and washed with water (15 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was purified by silica gel column chromatography using 10–40% EtOAc in heptane as the eluent to give (3R,4S,5S)-4-(acetoxy)-5-{4-acetamidopyrrolo[2,1-f][1,2,4]triazine-7-yl}-4-methyl-2-methyleneoxacyclopentane-3-yl acetate (270 mg, 46%) as a grayish-white solid. LCMS (ESI): m / z 389.2 [M+H]+.

[0156] Step 7: Synthesis of (2R,3S,4S,5S)-5-(4-acetamidopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluoro-2-(iodomethyl)-4-methyltetrahydrofuran-3,4-dimethyldiacetate: AgF (440.99 mg, 3.475 mmol) was added to a stirred solution of (3R,4S,5S)-4-(acetoxy)-5-{4-acetamidopyrrolo[2,1-f][1,2,4]triazin-7-yl}-4-methyl-2-methyleneoxacyclopentane-3-ylacetate (270 mg, 0.695 mmol) in anhydrous DCM (3 mL, 47.192 mmol) at 0 °C, followed by the addition of I2 (352.89 mg, 1.390 mmol) in DCM. The reaction mixture was stirred at 0°C for 10 minutes, then heated to room temperature and stirred for another 2 hours to form a solid precipitate. After the reaction was complete, the precipitate was filtered and washed with ACN to give (2R,3S,4S,5S)-4-(acetoxy)-5-{4-acetamidopyrrolo[2,1-f][1,2,4]triazine-7-yl}-2-fluoro-2-(iodomethyl)-4-methyloxacyclopentane-3-yl acetate (245It is a white solid (mg, 66%). LCMS (ESI): m / z 535.1 [M+H]+.

[0157] Step 8: Synthesis of (2S,3S,4S,5S)-5-(4-acetamidopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-((benzoyloxy)methyl)-2-fluoro-4-methyltetrahydrofuran-3,4-dimethyldiacetate: At room temperature, sodium benzoate (539.43 mg, 3.740 mmol) and 15-crown-5 ether (1.65 g, 7.480 mmol) were added to a stirred solution of (2R, 3S,4S,5S)-4-(acetoxy)-5-{4-acetamidopyrrolo[2,1-f][1,2,4]triazin-7-yl}-2-fluoro-2-(iodomethyl)-4-methyloxacyclopentane-3-ylacetate (200 mg, 0.374 mmol) in DMSO (5 mL). The resulting reaction mixture was stirred at 80 °C for 48 h. After the reaction was complete, the mixture was diluted with EtOAc (20 mL) and washed with ice-cold water (3 x 10 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was purified by silica gel column chromatography using 20–50% EtOAc in heptane as the eluent to give methyl benzoate [(2S,3S,4S,5S)-3,4-bis(acetoxy)-5-{4-acetamidopyrrolo[2,1-f][1,2,4]triazin-7-yl}-2-fluoro-4-methyloxacyclopentan-2-yl] ester (50 mg, 25%) as a white solid. LCMS (ESI): m / z 529.1 [M+H]+.

[0158] Step 9: Synthesis of (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-(hydroxymethyl)-2-methoxy-4-methyltetrahydrofuran-3,4-diol (3): A solution of methyl benzoate [(2S,3S,4S,5S)-3,4-bis(acetoxy)-5-{4-acetamidopyrrolo[2,1-f][1,2,4]triazin-7-yl}-2-fluoro-4-methyloxacyclopentan-2-yl]methyl ester (40 mg, 0.076 mmol) in NH3 (7 M, 5 mL in MeOH) was stirred at room temperature for 6 h. After the reaction was complete, the reaction mixture was concentrated under vacuum. The residue was purified by preparative HPLC to obtain (2R,3S,4R,5S)-5-{4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl}-2-(hydroxymethyl)-2-methoxy-4-methyloxacyclopentane-3,4-diol (1.4 mg, 6%), as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ7.82 (s, 1H) , 7.64 (s , 2H) , 6.84 (d , J = 4.4 Hz, 1H) , 6.72 (d , J = 4.4 Hz, 1H) , 5.55 (s , 1H) , 4.95 (d , J = 6.0 Hz, 1H) , 4.49 (d, J = 9.2 Hz, 1H), 4.32 (s, 1H), 3.93 (d, J = 9.2 Hz, 1H), 3.69 (d, J = 5.6 Hz, 1H), 3.48 (d, J = 11.2 Hz, 1H), 3.27 (s, 3H) , 0.75 (s, 3H). LCMS(ESI): m / z 311.1 [M+H]+. Specification 44 / 81 pages 58 CN 121358746 A

[0159] Compounds 19, 34 and 51, etc., were synthesized using a procedure similar to that used for synthesizing compound 3.

[0160] Example 4 Synthesis of compounds 4 and 5 Step 1: Synthesis of (2R,3R,4S,5S)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(iodomethyl)tetrahydrofuran-3,4-diol: PPh3 (1.2 g, 4.5 mmol) and imidazole (503 mg, 7.4 mmol) were added to a solution of (2R,3R,4S,5R)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (1.06 g, 3.7 mmol) in anhydrous THF (12 mL), and the resulting reaction mixture was stirred at room temperature for 30 min. Iodine (1.15 g, 4.5 mmol) was added to the above reaction mixture at 0 °C. The reaction system was stirred at room temperature for 12 h. After the reaction was complete, the reaction was quenched with a saturated NaHCO3 aqueous solution. The resulting mixture was concentrated under vacuum. The residue was diluted with DCM and extracted three times. The combined organic layers were dried over anhydrous sodium sulfate, and the filtrate was concentrated under vacuum to give the crude product (2R, 3R, 4S, 5S)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(iodomethyl)tetrahydrofuran-3,4-diol. LCMS (ESI): m / z 396.1 [M+H]+.

[0161] Step 2: Synthesis of (2R,3R,4S)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-methylenetetrahydrofuran-3,4-diol: Synthesis of (2R,3R,4S,5S)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(iodomethyl)tetrahydrofuran-3,4-diol at 0°C3,4-Diol (from the crude product of step 1) was added to a solution of DBU (8.6 mL, 55.6 mmol) in anhydrous THF (15 mL). The resulting reaction mixture was stirred at room temperature for 12 h. After the reaction was complete, AcOH was added to adjust the pH to 7, followed by the addition of water. The resulting mixture was extracted with EtOAc. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum to give the crude product (2R,3R,4S)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-methylenetetrahydrofuran-3,4-diol. The crude product was used for the next step without further purification. LCMS (ESI): m / z 268.0 [M+H]+.

[0162] Step 3: Synthesis of (2S,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol (4) and (2R,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol (5): mCPBA was added to a stirred solution of (2R,3R,4S)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-methylenetetrahydrofuran-3,4-diol (from the crude product of Step 2, 230 mg, 0.86 mmol) in anhydrous DCM (6 mL) at 0 °C. (297 mg, 1.7 mmol), followed by the addition of TEA.3HF (0.71 mL, 4.3 mmol). The reaction mixture was stirred at 0 °C for 40 minutes. After the reaction was complete, the reaction mixture was concentrated under vacuum. The residues were purified by reversed-phase preparative HPLC to give the desired compounds 4 and 5 (3 mg, 6%; 3 mg, 6%). Compound 4: ¹H NMR (400 MHz, DMSO-d⁶) δ 8.69 (d, J = 1.4 Hz, 1H), 7.87 (d, J = 3.7 Hz, 1H), 6.79 (d, J = 3.7 Hz, 1H), 6.47 (d, J = 3.0 Hz, 1H), 4.54 (dd, J = 16.4, 6.4 Hz, 1H), 4.44 (t, J = 4.8 Hz, 1H), 3.60 – 3.53 (m, 2H). LCMS (ESI): Specification 45 / 81, page 59, CN 121358746, A m / z 304.2 [M+H]⁺. Compound 5: ¹H NMR (400 MHz, DMSO) ¹H NMR (400 MHz, DMSO-d6) δ8.64 (s, 1H), 7.84 – 7.71 (d, 1H), 6.80 (d, J = 3.8 Hz, 1H), 6.44 (t, J = 7.1 Hz, 1H), 4.84 (dt, J = 7.3, 3.5 Hz, 1H), 4.16 – 4.05 (m, 1H), 3.73 (s, 1H), 3.52 – 3.40 (m, 1H). LCMS(ESI): m / z 304.2 [M+H]+.

[0163] Compounds 13, 27, and 29 were synthesized using a procedure similar to that used for compound 4.

[0164] Example 5 Synthesis of Compound 20 Step 1: Synthesis of ((5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofurano[2,3-d][1,3]dioxacyclopenten-5-yl)methanol: Benzyl bromide (3.62 g, 21.3 mmol) was added to a stirred solution of ((3aR,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofurano[2,3-d][1,3]dioxacyclopenten-5,5-diyl)methanol (6 g, 19.35 mmol) and 60% NaH (1.08 g, 27.09 mmol) in anhydrous N,N-dimethylformamide (60 mL). The resulting mixture was stirred at room temperature for 1 h, then quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ((5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofurano[2,3-d][1,3]dioxacyclopenten-5-yl)methanol (5.2 g, 67%) as a yellow solid. LCMS (ESI): m / z 423.0 [M+Na]+.

[0165] Step 2: Synthesis of (5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)-2,2-dimethyltetrahydrofurano[2,3-d][1,3]dioxane: DAST (6.28 g, 39 mmol) was added to a stirred solution of (3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-ol (5.2 g, 13 mmol) in toluene (52 mL) at 0 °C and N2. The resulting mixture was stirred at 60 °C for 5 h, then quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous sodium sulfate and subjected to a reduction reaction.Concentrate under pressure. Purify the residue by silica gel column chromatography to obtain (5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)-2,2-dimethyltetrahydrofurano[2,3-d][1,3]dioxane (2.7 g, 52%), as a yellow oil. LCMS (ESI): m / z 425.1 [M+Na]+.

[0166] Step 3: Synthesis of (3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)tetrahydrofuran-2,3-dimethyldiacetate: Acetic anhydride (0.68 g, 6.7 mmol) and H2SO4 (65.7 mg, 0.67 mmol) were added to (5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)-2,2-dimethyltetrahydrofurano[2,3-d][1,3]dioxane (2.7 g, 6.7 mmol) in acetic acid (36 mL) at 10 °C. The resulting mixture was stirred at room temperature for 1.5 h. After the reaction was complete, the reaction was quenched with H2O and extracted with EtOAc. The combined organic layers were dried over anhydrous sulfuric acid (see page 46 / 81 of the instruction manual, CN 121358746 A) and concentrated under reduced pressure to obtain a crude product. The residue was purified by silica gel column chromatography to give (3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)tetrahydrofuran-2,3-dimethyldiacetate (2.3 g, 77%), as a yellow solid. LCMS (ESI): m / z 469.0 [M+Na]+.

[0167] Step 4: Synthesis of (2R,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(fluoromethyl)tetrahydrofuran-3-yl acetate: Add (3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)tetrahydrofuran-2,3-dimethyl diacetate (1.6 g, 3.76 mmol) and TMSOTf (834.72 mg, 3.76 mmol) to a mixture of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (577.42 mg, 3.76 mmol) and BSA (764.9 mg, 3.76 mmol) in ACN (32 mL). The reaction system was stirred at 80 °C for 3 h. After the reaction was complete, the reaction was quenched with NaHCO3 (aqueous solution) and extracted with EtOAc. The combined organic layers were dried, concentrated, and purified by silica gel column chromatography to obtain (2R,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-(4-chloro-7H-pyrrolo).[2,3-d]pyrimidin-7-yl)-5-(fluoromethyl)tetrahydrofuran-3-yl acetate (215 mg, 11%), is a yellow solid. LCMS (ESI): m / z 540.0 [M+H]+.

[0168] Step 5: Synthesis of (2R,3R,4S,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)tetrahydrofuran-3-ol: NH3H2O ​​(4 mL) was added to a solution of (2R,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(fluoromethyl)tetrahydrofuran-3-yl acetate (215 mg, 0.4 mmol) in 1,4-dioxane (4 mL), and the resulting mixture was stirred at 100 °C for 25 h. The mixture was concentrated and purified by silica gel column chromatography to give (2R,3R,4S,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)tetrahydrofuran-3-ol (180 mg, 94% yield) as a yellow solid. LCMS (ESI): m / z 479.2 [M+H]+.

[0169] Step 6: Synthesis of (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(fluoromethyl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol (20): BCl3 (3.8 mL, 3.76 mmol, 1M) was added to a stirred solution of (2R,3R,4S,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-(fluoromethyl)tetrahydrofuran-3-ol (180 mg, 0.376 mmol) in DCM (3 mL) at -78 °C and N2. The resulting mixture was stirred at -78 °C for 2 h and then quenched with MeOH (10 mL). Excess solvent was removed under reduced pressure. The residue was purified by preparative HPLC to give (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(fluoromethyl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol as a solid (20, 35 mg of compound, 31% yield).

[0170] 1H NMR (400 MHz, MeOD-d4) δ 8.06 (s, 1H), 7.32 (d, J = 3.1 Hz, 1H), 6.61 (d, J = 2.7 Hz, 1H),5.98 (d, J = 7.7 Hz, 1H), 4.84 – 4.83 (m, 1H), 4.74 (d, J = 9.8 Hz, 1H), 4.60 (dd, J = 20.2, 9.8 Hz, 1H), 4.45 (d, J = 9.8 Hz, 1H), 4.32 (d, J = 5.1 Hz, 1H), 3.76 (s, 2H). 19F NMR (377 MHz, MeOD-d4) δ-236.74. LCMS (ESI): m / z 299.0 [M+H]+.

[0173] Example 6 Synthesis of Compound 30 Specification 47 / 81 pages 61 CN 121358746 A Step 1: Synthesis of (1R,2S,3R,5R)-3-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol: TEA (3.03 mg, 30.0 mmol) was added to a solution of 2-(4,6-dichloropyrimidin-5-yl)acetaldehyde (1.91 g, 10.0 mmol) and (1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol hydrochloride (1.84 g, 10.0 mmol) in EtOH (50 mL), and the reaction mixture was stirred at 80 °C for 24 hours. After the reaction was complete, the mixture was concentrated under vacuum. The residue was dissolved in a saturated NaHCO3 solution and then extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and then filtered. The filtrate was concentrated under reduced pressure to give crude (1R,2S,3R,5R)-3-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol (2.83 g), a yellow gel, which was used for the next step without further purification. LCMS (ESI): m / z = 284.1 [M+H]+.

[0174] Step 2: Synthesis of [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopentano[d][1,3]dioxacyclopenten-6-yl]methanol: to (1R,2S,3R,5R)-3-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol (2.83 g, 10.0 mmol) and 2,2-dimethoxypropane (2.08 g, 20 mmol) in acetone (604-Methylbenzenesulfonic acid hydrate (194 mg, 1 mmol) was added to a solution in mL. The mixture was stirred at room temperature for 2 h, then refluxed for 24 h. After the reaction was complete, the reaction was quenched by Et3N and then concentrated under reduced pressure. The residue was treated with saturated NaHCO3 solution and brine. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and then filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to give [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopentano[d][l,3]dioxacyclopenten-6-yl]methanol (3.0 g, 93% yield) as a yellow solid. LCMS (ESI): m / z = 324.1 [M+H]+.

[0175] Step 3: Synthesis of 7-[(3aS,4R,6S,6aR)-6-(iodomethyl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxacyclopenten-4-yl]-4-chloropyrrolo[2,3-d]pyrimidine: I2 (4.72 g, 18.57 mmol) was added to a solution of PPh3 (4.86 g, 9.29 mmol) and imidazole (1.94 g, 19.51 mmol) in THF (30 mL). The mixture was stirred at room temperature and under N2 for 15 minutes, and then a solution of [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopentano[d][l,3]dioxane-6-yl]methanol (3000 mg, 9.29 mmol) in THF (20 mL) was added. The mixture was stirred at room temperature and under N2 for 1.5 h. After the reaction was complete, the reaction was quenched with saturated Na2S2O3 solution and then extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, and then filtered. The filtrate was concentrated under vacuum. The residue was purified by column chromatography to obtain 7-[(3aS,4R,6S,6aR)-6-(iodomethyl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxacyclopenten-4-yl]-4-chloropyrrolo[2,3-d]pyrimidine (3.0 g, 69% yield), as a yellow solid. LCMS (ESI): m / z = 434.1 [M+H]+.

[0176] Step 4: 4-chloro-7-((3aS,4R)-6-((3aS,4R)-6-((3aS,6 ...Synthesis of pyrimidine (3aS, 4R, 6S, 6aR)-6-(iodomethyl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxacyclopenta-4-yl]-4-chloropyrrolo[2,3-d]pyrimidine: 1 M t-BuOK was added to a solution of 7-[(3aS, 4R, 6S, 6aR)-6-(iodomethyl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxacyclopenta-4-yl]-4-chloropyrrolo[2,3-d]pyrimidine (3000 mg, 6.93 mmol) in THF (20 mL). The reaction mixture was stirred at 0 °C for 30 min. After the reaction was complete, the reaction was quenched with saturated NH4Cl aqueous solution. The mixture was extracted with EtOAc. The separated organic layers were combined, washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give 4-chloro-7-((3aS,4R,6aR)-2,2-dimethyl-6-methylenetetrahydro-4H-cyclopentano[d][1,3]dioxacyclopenten-4-yl)-7H-pyrrolo[2,3-d]pyrimidine (2.12 g, 94% yield) as a colorless foam. LCMS (ESI): m / z = 306.1 [M+H]+.

[0177] Step 5: Synthesis of (3aS,4R,6R,6aS)-6-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrocyclopentano[d][1,3]dioxacyclopenten-4-ol: Add K2O5O4·2H2O to a mixture of 4-chloro-7-((3aS,4R,6aR)-2,2-dimethyl-6-methylenetetrahydro-4H-cyclopentano[d][1,3]dioxacyclopenten-4-yl)-7H-pyrrolo[2,3-d]pyrimidine (1300 mg, 4.024 mmol) and NMO (943 mg, 8.06 mmol) in a mixed solvent of acetone (26 mL) and H2O (5.2 mL). (30.3 mg, 0.098 mmol). The mixture was stirred at room temperature for 20 h. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give (3aS,4R,6R,6aS)-6-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrocyclopenta[d][l,3]dioxane-4-ol (1300 mg, 95% yield), as a pale yellow foam. LCMS (ESI): m / z = 340.0 [M+H]+.

[0178] Step 6: Benzoic acid [(3aS,4R,6R]Synthesis of methyl 3a, 5, 6, 6a tetrahydrocyclopentano[d][l, 3]dioxane-4-yl]tetrahydrocyclopentano[d][l, 3]dioxane-4-yl]tetrahydrocyclopentano[d][l, 3]dioxane-4-yl]tetrahydrocyclopentano[d][l, 3]dioxane-4-yl]tetrahydrocyclopentano[d][l, 3]dioxane-4-yl]tetrahydrocyclopentano[d][l, 3]dioxane-4-yl]ol (1300 mg, 3.83 mmol), DMAP (46.7 mg, 0.383 mmol) and Et3N (581 mg, 5.75 mmol) in DCM (35 mL) was prepared by adding benzoyl chloride (1079 mg) dropwise to a solution of (3aS, 4R, 6R, 6aS)-6-(4-chloropyrrolo[2, 3-d]pyrimidin-7-yl)-4-(hydroxymethyl)-2, 2-dimethyl-3a, 5, 6, 6a tetrahydrocyclopentano[d][l, 3]dioxane-4-yl]ol (1300 mg, 3.83 mmol), DMAP (46.7 mg, 0.383 mmol) and Et3N (581 mg, 5.75 mmol) in DCM (35 mL). (mg, 7.67 mmol). The mixture was stirred at room temperature for 3 h. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give methyl benzoate [(3aS,4R,6R,6aS)-6-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-4-hydroxy-2,2-dimethyl-3a,5,6,6atetrahydrocyclopenta[d][l,3]dioxane-4-yl] ester (1.3 g, 94% yield) as a white foam. LCMS (ESI): m / z = 444.1 [M+H]+.

[0179] Step 7: Synthesis of methyl benzoate ((3aS,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxacyclopenten-4-yl) ester: DAST (436.5 mg, 2.71 mmol) was added to a solution of methyl benzoate ((3aS,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-hydroxy-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxacyclopenten-4-yl) ester (600 mg, 1.355 mmol) in anhydrous DCM (30 mL) at 0 °C. The reaction mixture was stirred at 0°C for 1 hour. The mixture was quenched with a saturated aqueous solution of NaHCO3 and extracted with DCM. The separated organic layers were combined, washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give benzoic acid ((3aS,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxane-4-yl)methyl benzoate (62(mg, 10%), a white foamy substance. LCMS (ESI): m / z = 446.2 [M+H]+.

[0180] Step 8: Synthesis of ((3aS,4S,6R,6aS)-6-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2,2-dimethyltetrahydro-4H-cyclopentano[d][1,3]dioxacyclopenten-4-yl)methanol: Concentrated ammonia (2 mL) was added to a solution of methyl benzoate ((3aS,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2,2-dimethyltetrahydro-4H-cyclopentano[d][1,3]dioxacyclopenten-4-yl) in dioxane (2 mL). The reaction system was then stirred at 100 °C for 16 hours. The solvent was removed under vacuum to yield ((3aS,4S,6R,6aS)-6-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxacyclopenten-4-yl)methanol (20 mg, 71%), as a pale yellow foam. LCMS: m / z = 323.2 [M+H]+.

[0181] Step 9: Synthesis of (1S,2S,3S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-3-(hydroxymethyl)cyclopentane-1,2-diol (9): 4M HCl (0.5 mL) was added to a solution of ((3aS,4S,6R,6aS)-6-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2,2-dimethyltetrahydro-4H-cyclopentano[d][1,3]dioxacyclopenten-4-yl)methanol (2 mg, 0.0062 mmol) in THF (1 mL). The reaction system was then stirred at 0 °C for 1 hour. After the reaction was complete, the solvent was removed under vacuum, and the product was purified by reversed-phase preparative HPLC to obtain (1S,2S,3S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-3-(hydroxymethyl)cyclopentane-1,2-diol (compound 9, 1.5 mg, 83%), a white foamy substance. ¹H NMR (400 MHz, methanol-d⁴) δ 8.21 (s, 1H), 7.49 (d, J = 3.7 Hz, 1H), 6.85 (d, J = 3.6 Hz, 1H), 5.22 (dd, J = 17.0, 9.7 Hz, 1H), 4.47 (t, J = 6.7 Hz, 1H), 4.21 (dd, J = 13.0, 6.2 Hz, 1H), 3.88 – 3.69 (m, 2H), 2.52 (ddd, J = 20.0, 14.8, 9.5 Hz, 1H), 2.42 – 2.25 (m, 1H). LCMS(ESI): m / z= 283.0 [M+H]+.

[0182] Example 7 Synthesis of Compound 47 Synthesis of (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-dimethylbis(2-methylpropionate) (47): At room temperature, isobutyric acid (511 mg, 5.81 mmol), 4-dimethylaminopyridine (65 mg, 0.53 mmol), and dicyclohexylcarbodiimide (1.2 g, 500 mg, 1.76 mmol) were added to a solution of (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol (compound 1, 500 mg, 1.76 mmol) in dichloromethane (10 mL). 5.81 mmol). The mixture was stirred for 2 hours. After the reaction was complete, the insoluble solids were removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-dimethylbis(2-methylpropionate) (compound 47,450 mg, 52% yield), as a white solid. ¹H NMR (300 MHz, DMSO-d₆) δ 8.09 (s, ¹H), 7.37 (d, J = 3.6 Hz, ¹H), 7.17 (s, 2H), 6.64 (d, J = 3.6 Hz, 1H), 6.50 (d, J = 1.8 Hz, 1H), 6.25 (dd, J = 19.1, 7.0 Hz, 1H), 5.93 (dd, J = 7.0, 2.1 Hz, 1H), 4.42 – 4.23 (m, 2H), 2.63 (dt, J = 13.9, 6.9 Hz, 1H). (Note: This text also includes references to other instruments and spectral density values, which are not translated as they are not part of the main NMR data.) Hz, 2H) , 2.48 – 2.40 (m, 1H) , 1.15 (d , J = 6.9 Hz, 6H) , 1.13 – 1.02 (m, 9H) , 0.97 (d, J= 7.0 Hz, 3H). LCMS (ESI): m / z 495.3 [M +H]+.

[0183] Compounds 46 and 73 were synthesized using a procedure similar to that used for the synthesis of compound 47.

[0184] Example 8 Synthesis of compounds 48 and 49 Step 1: Synthesis of isopropyl (2S)-2-{[chloro(phenoxy)phosphoryl]amino}propionate: A solution of isopropyl (2S)-2-aminopropionate hydrochloride (3 g, 17.8 mmol) in DCM (60 mL) was treated with phenoxyphosphonyl dichloride (4.15 g, 19.6 mmol) at -78 °C and under a nitrogen atmosphere for 30 min, followed by the dropwise addition of TEA (3.62 g, 35.7 mmol) at -78 °C. The resulting mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with MTBE (30 mL). The resulting mixture was filtered, and the filter cake was washed with MTBE (2 x 10 mL). The filtrate was concentrated under reduced pressure. The crude product (chloro(phenoxy)phosphoryl)-L-alanine isopropyl ester (4.2 g) was used directly in the next step without further purification. LCMS (ESI) m / z 306.1 [M+H]+.

[0185] Step 2: Synthesis of isopropyl propionate (48 and 49) of (2S)-2-({[(2S,3S,4R,5R)-5-{4-aminopyrrolo[2,3-d]pyrimidin-7-yl}-2-fluoro-3,4-dihydroxyoxacyclopentan-2-yl]methoxy(phenoxy)phosphoryl}amino)propionate: 1-methyl-1H-imidazolium (1.27 g, 15.4 mmol) was added dropwise to a stirred solution of (2S,3S,4R,5R)-5-{4-aminopyrrolo[2,3-d]pyrimidin-7-yl}-2-fluoro-2-(hydroxymethyl)oxacyclopentan-3,4-diol (compound 1, 800 mg, 2.81 mmol) in THF (10 mL) and trimethyl phosphate (1 mL) under a nitrogen atmosphere. A solution of (2S)-2-{[chloro(phenoxy)phosphoryl]amino}propionate isopropyl ester (2.15 g, 7.03 mmol) in THF (4 mL). The resulting mixture was stirred at room temperature for another 1 h. The reaction was quenched with H2O at 0 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine (1 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC and preparative SFC to give (2S)-2-({[(2S,3S,4R,5R)-5-{4-aminopyrrolo[2,3-d]pyrimidine-7- ... (Instructions 51 / 81 pages 65 CN 121358746 A)Isopropyl propionate (compound 48, 2.4 mg, second peak in preparative SFC) and (2S)-2-({[(2S,3S,4R,5R)-5-{4-aminopyrrolo[2,3-d]pyrimidin-7-yl}-2-fluoro-3,4-dihydroxyoxacyclopentan-2-yl]methoxy(phenoxy)phosphoryl}amino)propionate (compound 49, 5.3 mg, first peak in preparative SFC) are white solids. LCMS m / z [M+H]+ 554.1.

[0186] Compound 48: ¹H NMR (300 MHz, DMSO-d6) δ 8.08 (s, 1H), 7.32 (t, J = 7.7 Hz, 2H), 7.24 (d, J = 3.6 Hz, 1H), 7.15 (m, 5H), 6.62 (d, J = 3.7 Hz, 1H), 6.35 (d, J = 3.2 Hz, 1H), 6.06 (dd, J = 13.1, 10.1 Hz, 1H), 5.81 (d, J = 5.6 Hz, 1H), 5.40 (d, J = 8.5 Hz, 1H), 4.82 (m, 1H) , 4.58 (m, 1H) , 4.46 (m, 1H) , 4.14 (m, 2H) , 3.83 – 3.65 (m, 1H) , 1.22 – 0.98 (m, 9H). 19F NMR (282 MHz, DMSO‑d6) δ‑120.63. Compound 49: 1H NMR (300 MHz, DMSO-d6) δ 8.08 (s, 1H), 7.34 (t, J = 7.8 Hz, 2H), 7.24 – 7.08 (m, 6H), 6.63 (d, J = 3.7 Hz, 1H), 6.36 (d , J = 3.0 Hz, 1H) , 6.03 (dd , J = 13.4, 9.9 Hz, 1H) , 5.82 (d , J = 5.4 Hz, 1H) , 5.43 (d , J = 8.7 Hz, 1H) , 4.83 (m, 1H) , 4.58 (m, 1H) , 4.46 (s, 1H) , 4.17 (m, 2H) , 3.69 (m, 1H) , 1.13 (d, J = 5.8 Hz, 9H). 19FNMR (282 MHz, DMSO-d6) δ -120.27.

[0188] Compound 74 was synthesized using a procedure similar to that used for synthesizing compounds 48 and 49.

[0189] Example 9 Synthesis of compounds 57, 58 and 59 Step 1: Synthesis of (4S,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}oxacyclopentan-2-one: Imidazole (64.41 g, 946.1 mmol) and DMAP (2.31 g, 18.92 mmol) and TBSCl (119.8 g, 794.8 mmol) were added to a solution of deoxyribonucleolone (50 g, 378.458 mmol) in DMF (500 mL) at 0 °C. The mixture was stirred at 20 °C for 12 h. The mixture was quenched with NaHCO3 (500 mL) and extracted with EtOAc (3 x 500 mL), then dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated. The residue was purified by silica gel column chromatography to give (4S,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}oxacyclopentan-2-one (110 g, 81%) as a white solid. ¹H NMR (300 MHz, chloroform-d) δ 4.52 (m, 1H), 4.35 (m, 1H), 3.87–3.74 (m, 2H), 2.84 (dd, J = 17.6, 6.7 Hz, 1H), 2.40 (dd, J = 17.6, 2.6 Hz, 1H), 0.91 (s, 18H), 0.14–0.06 (m, 12H).

[0190] Step 2: Synthesis of (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-fluorooxetane-2-one: LiHMDS (232.9 mL, 233.0 mmol) was added to a solution of (4S,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}oxetane-2-one (60 g, 166.4 mmol) and NFSI (65.58 g, 208.0 mmol) in THF (1200 mL) at -78 °C. The mixture was stirred at -78 °C for 2 h. The reaction was quenched with NH4Cl at -78 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were rinsed with brine (300 mL).Washed (mL), dried over anhydrous Na2SO4. Filtered, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-fluorooxocyclopentan-2-one (30 g, 48%), as a colorless oil.

[0191] Step 3: Synthesis of (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxetane-2-one: LiHMDS (184.9 mL, 174.9 mmol) was added to a solution of (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-fluorooxetane-2-one (28 g, 7.98 mmol) and NCS (23.52 g, 147.90 mmol) in THF (110 mL) at -78 °C. The mixture was stirred at -78 °C for 2 h. The reaction was quenched with saturated NH4Cl (aqueous solution) at -78 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxetane-2-one (12 g, 39%) as a yellow oil. 1H NMR (300 MHz, chloroform-d) δ 4.60 (dd, J = 12.0, 5.7 Hz, 1H), 4.40 – 4.33 (m, 1H), 4.00 (dd, J = 12.1, 3.9 Hz, 1H), 3.90 – 3.83 (m, 1H) , 0.95 (s, 9H) , 0.91 (s, 9H) , 0.23 (s, 3H) , 0.19 (s, 3H) , 0.11 (d, J = 2.7 Hz, 6H).

[0192] Step 4: Synthesis of (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-ol: Synthesis of (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-one (12Li(t-BuO)3AlH (92.63 mL, 82.63 mmol) was added to a solution of 29.05 mmol in THF (120 mL). The mixture was stirred at 20 °C for 2 h and then quenched with saturated NH4Cl (aqueous solution) at 0 °C. The resulting mixture was extracted with EA. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-ol (12.2 g, 100%) as a yellow oil. Instruction manual, pages 53 / 81, 67 CN 121358746 A

[0193] Step 5: Synthesis of N-(tert-butyloxycarbonyl)-N-{9-[(2R,3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-yl]-6-chloropurine-2-yl}carbamate: To (3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-ol (11.25 g, 27.1 mmol) and N- (tert-Butyloxycarbonyl)-N-(6-chloro-9H-purin-2-yl)carbamate tert-butyl ester (12 g, 32.53 mmol) was added to a solution of PPh3 (10.68 g, 40.65 mmol) in THF (320 mL). The mixture was cooled to 0 °C, DIAD (6.6 g, 37.95 mmol) was added, and the mixture was stirred at 70 °C for 1 h. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain N-(tert-butyloxycarbonyl)-N-{9-[(2R,3S,4R,5R)-4-[(-tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-yl]-6-chloropurine-2-yl} tert-butyl carbamate (4.6 g, 22%), as a white solid. LCMS (ESI): m / z 766.7 [M+H]+.

[0194] Step 6: N-(tert-butyloxycarbonyl)-N-{9-[(2R,3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]methyl}Synthesis of tert-butyl carbamate: Methylamine (33% in ethanol) was added to a solution of N-(tert-butyloxycarbonyl)-N-{9-[(2R,3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-yl]-6-chloropurine-2-yl}carbamate (4.6 g, 6.01 mmol, 1 equivalent) in EtOH (45 mL). The mixture was stirred at 60 °C for 2 h, and the resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography to obtain N-(tert-butyloxycarbonyl)-N-{9-[(2R,3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxocyclopentan-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (4 g, 98%), as a grayish-white solid. LCMS (ESI): m / z 661.5 [M+H]+.

[0195] Step 7: Synthesis of N-{9-[(2R,3S,4R,5R)-3-chloro-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate: KF (3.51 g, 60.48 mmol) was added to a solution of N-{9-[(2R,3S,4R,5R)-4-[(tert-butyldimethylsilyl)oxy]-5-{[(tert-butyldimethylsilyl)oxy]methyl}-3-chloro-3-fluorooxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (4 g, 6.048 mmol) in MeOH (80 mL). The mixture was stirred at 60 °C for 6 h, and the resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography to obtain N-{9-[(2R,3S,4R,5R)-3-chloro-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (2.5 g, 96%), a white solid. LCMS (ESI): m / z 433.0 [M+H]+.

[0196] Step 8: Synthesis of N-{9-[(2R,3S,4R,5S)-3-chloro-3-fluoro-4-hydroxy-5-(iodomethyl)oxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate:2.5 g (5.776 mmol) of fluoro-4-hydroxy-5-(hydroxymethyl)oxacyclopentan-2-yl]-6-(methylamino)purine-2-yl}carbamate tert-butyl ester (4.5 g, 5.776 mmol) was added to a solution of 40 mL of THF with PPh3 (4.545 g, 17.33 mmol), pyridine (4.569 g, 57.76 mmol), and I2 (2.932 g, 11.55 mmol). The mixture was stirred at 20 °C for 12 h. The resulting mixture was concentrated under vacuum. The residue was eluted with PE / THF (2 / 1) and purified by silica gel column chromatography to give N-{9-[(2R,3S,4R,5S)-3-chloro-3-fluoro-4-hydroxy-5-(iodomethyl)oxepane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (3 g, 96%) as a yellow oil. LCMS (ESI): m / z 543.0 [M+H]+.

[0197] Step 9: Synthesis of N-{9-[(2R,3S,4R)-3-chloro-3-fluoro-4-hydroxy-5-methyleneoxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate: DBU (3.37 g, 22.11 mmol) was added to a solution of N-{9-[(2R,3S,4R,5S)-3-chloro-3-fluoro-4-hydroxy-5-(iodomethyl)oxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (3 g, 5.528 mmol) in THF (50 mL). The mixture was stirred at 20 °C for 7 h, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give N-{9-[(2R,3S,4R)-3-chloro-3-fluoro-4-hydroxy-5-methyleneoxepane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (830 mg, 36%) as a white solid. LCMS (ESI): m / z 415.2 [M+H]+.

[0198] Step 10: Synthesis of N-{9-[(2R,3S,4R,5R)-3-chloro-3,5-difluoro-4-hydroxy-5-(iodomethyl)oxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate: N-{9-[(2R,3S,4R)-3-chloro-3-fluoro-4-hydroxy-5-methyleneoxetane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (600 mg, 1.446 mmol) was synthesized at 0 °C using MeCN.TEA·3HF (349.8 mg, 2.169 mmol) was added to the solution in (6 mL). The mixture was stirred for 10 min. NIS (488.1 mg, 2.169 mmol) was added at 0 °C, and the mixture was heated to room temperature and stirred for 1 h. After the reaction was complete, the reaction was slowly quenched with ice-cold water and extracted with EtOAc. The resulting mixture was concentrated under reduced pressure, and the crude product N-{9-[(2R,3S,4R,5R)-3-chloro-3,5-difluoro-4-hydroxy-5-(iodomethyl)oxepane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (1.1 g, crude) was used directly for the next step without further purification. LCMS (ESI): m / z 561.0 [M+H]+.

[0199] Step 11: Synthesis of (2R,3R,4S,5R)-5-{2-[(tert-butyloxycarbonyl)amino]-6-(methylamino)purine-9-yl}-4-chloro-2,4-difluoro-2-(iodomethyl)oxetane-3-ylbenzoate: Benzoyl chloride (1378.8 mg, 9.80 mmol) was added to a solution of N-{9-[(2R,3S,4R,5R)-3-chloro-3,5-difluoro-4-hydroxy-5-(iodomethyl)oxetane-2-yl]-6-(methylamino)purine-2-yl}carbamate (1.1 g, 1.96 mmol) in pyridine (8 mL) at 0 °C. The mixture was stirred for 45 minutes. After the reaction was complete, the mixture was quenched with an aqueous solution of ammonium chloride and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude substance was purified by column chromatography to give (2R,3R,4S,5R)-5-{2-[(tert-butyloxycarbonyl)amino]-6-(methylamino)purine-9-yl}-4-chloro-2,4-difluoro-2-(iodomethyl)oxacyclopentane-3-ylbenzoate (600 mg, 46%). LCMS (ESI): m / z 665.1 [M+ H]+.

[0200] Step 12: Synthesis of methyl benzoate [(2S,3R,4S,5R)-3-(benzoyloxy)-5-{2-[(tert-butyloxycarbonyl)amino]-6-(methylamino)purine-9-yl}-4-chloro-2,4-difluorooxetane-2-yl]: Sodium benzoate (1.040 g, 7.224 mmol) was added to a solution of (2R,3R,4S,5R)-5-{2-[(tert-butyloxycarbonyl)amino]-6-(methylamino)purine-9-yl}-4-chloro-2,4-difluoro-2-(iodomethyl)oxetane-3-ylbenzoate (600 mg, 0.903 mmol) in DMSO (10 mL). The mixture was stirred at 100 °C for 12 minutes.The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl benzoate [(2S,3R,4S,5R)-3-(benzoyloxy)-5-{2-[(tert-butoxycarbonyl)amino]-6-(methylamino)purine-9-yl}-4-chloro-2,4-difluorooxetane-2-yl] ester (400 mg, 67%) as a yellow oil. LCMS (ESI): m / z 659.2 [M+H]+.

[0201] Step 13: Synthesis of methyl benzoate [(2S,3R,4S,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-3-(benzoyloxy)-4-chloro-2,4-difluorooxetane-2-yl] ester: A solution of methyl benzoate [(2S,3R,4S,5R)-3-(benzoyloxy)-5-{2-[(tert-butoxycarbonyl)amino]-6-(methylamino)purin-9-yl}-4-chloro-2,4-difluorooxetane-2-yl] ester (400 mg, 0.304 mmol) and HCl (1 mL, 4.0 mmol) in DCM (3 mL) was stirred at 20 °C for 4 h. The mixture was alkalized to pH = 7 with saturated NaHCO3 (aqueous solution). The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure to obtain methyl formate [(2S,3R,4S,5R)-5-[2-amino-6-(methylamino)purine-9-yl]-3-(benzoyloxy)-4-chloro-2,4-difluorooxetane-2-yl] (300 mg, 89%), a yellow oil. LCMS (ESI): m / z 559.2 [M+H]+.

[0202] Step 14: Synthesis of (2S,3R,4S,5R)-5-[2-amino-6-(methylamino)purine-9-yl]-4-chloro-2,4-difluoro-2-(hydroxymethyl)oxepane-3-ol (57): A solution of N-{9-[(2R,3S,4R,5S)-3-chloro-3,5-difluoro-4-hydroxy-5-(hydroxymethyl)oxepane-2-yl]-6-(methylamino)purine-2-yl} tert-butyl carbamate (280 mg, 0.621 mmol) in methylamine (33% in ethanol) was stirred at 20°C for 2 h. The resulting mixture was concentrated under vacuum. The crude product was purified by preparative HPLC to obtain (2S,3R,4S,5R)-5-[2-amino-6-(methylamino)purine-9-[M+H]-4-chloro-2,4-difluoro-2-(hydroxymethyl)oxacyclopentan-3-ol (compound 57, 95 mg, 51%), is a white solid. LCMS (ESI): m / z 351.0 [M+H]+.

[0203] Compounds 56, 60, 62, 63, 66, 68, 70, and 71 were synthesized using a procedure similar to that used for compound 57.

[0204] Step 15: Synthesis of isopropyl (2S)-2-({[(2S,3R,4S,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-chloro-2,4-difluoro-2-(hydroxymethyl)oxacyclopentan-3-ol (compound 57, 50 mg, 0.143 mmol) and (2S)-2-{[2,3,4 ...,3,4,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-chloro-2,4-difluoro-2-(hydroxymethyl)oxacyclopentan-3-ol (compound 57, 50 mg, 0.143 mmol)-3-ol (2S)-2-{[2,3,4,5R)-5-[2,3,4,5R)-5-[2,3,4,5R)-5-[2,3,4,5R)-5-[2,3,4,5R)-5-[2,3,4,5R]-5-[2,3,4,5R]-5-[2,3,4,5R]-5-[2,3,4,5R Isopropyl 5,6-pentafluorophenoxy(phenoxy)phosphoryl]amino}propionate (162 mg, 0.357 mmol) was added dropwise to a stirred mixture of THF (2 mL) and acetonitrile (0.2 mL) with 1-methyl-1H-imidazolium (29 mg, 0.357 mmol). The resulting mixture was stirred at room temperature for 2 h. MgCl2 (14 mg, 0.143 mmol) and DIEA (37 mg, 0.286 mmol) were added to the mixture at room temperature. The resulting mixture was stirred at room temperature for 1 h. After the reaction was complete, the reaction was quenched with water. The crude product was purified by preparative HPLC and SFC to give each isomer (compound 58, 8.4 mg, second peak in preparative SFC, and compound 59, 7.0 mg, first peak in preparative SFC) as a white solid. LCMS (ESI): m / z 619.2 [M+H]+.

[0205] Compound 62: ¹H NMR (400 MHz, DMSO-d6) δ 7.86 (s, 1H), 7.37 (t, J = 7.9 Hz, 3H), 7.29–7.21 (m, 2H), 7.19 (t, J = 7.3 Hz, 1H), 6.72 (d, J = 15.0 Hz, 2H), 6.21–6.13 (m, 2H), 6.07 (dd, J = 13.1, 10.0 Hz, 1H), 4.82 (m, 1H), 4.70 (brs, 1H), 4.33 (m, 1H), 3.85 – 3.73(m, 1H), 2.88 (s, 3H), 1.19 (d, J = 7.1 Hz, 3H), 1.12 (dd, J = 6.3, 4.0 Hz, 6H). 19F NMR (376 MHz, DMSO‑d6) δ‑116.58.

[0206] Compound 63: ¹H NMR (400 MHz, DMSO-d6) δ 7.85 (s, 1H), 7.41–7.29 (m, 3H), 7.17 (d, J = 7.6 Hz, 3H), 6.79 (s, 1H), 6.72 (d, J = 14.9 Hz, 1H), 6.15 (s, 2H), 6.10–6.02 (m, 1H), 4.84 (m, 1H), 4.63 (s, 1H), 4.43 (m, 1H), 3.81 (m, 1H), 2.88 (s, 3H), 1.23 (d, J = 7.6 Hz, 3H) J = 7.1 Hz, 3H), 1.14 (d, J = 6.2 Hz, 6H). 19F NMR (376 MHz, DMSO-d6) δ -116.28.

[0207] Compounds 61, 64, 65, 67 and 69 were synthesized using a procedure similar to that used for compounds 58 and 59. Specification 56 / 81 pages 70 CN 121358746 A

[0208] Example 10 Synthesis of compound 75 POCl3 (104 mg, 685 μmol, 63.5 μL) was added to a solution of 1 (130 mg, 457 μmol) and proton sponge (97.8 mg, 457 μmol) in PO (OMe)3 (1.30 mL) at -10°C. The mixture was stirred at 25°C and N2 for 1 hour. After the reaction was complete, the crude product s (182 mg, crude) proceeded to the next step without further purification.

[0209] (Bu3N)2H4P2O7 (0.6 M, 2.30 mL) and Bu3N (257 mg, 1388 μmol, 4.00 equivalent) were added to a solution of crude product (182 mg, 347 μmol) in PO(OMe)3 (1.30 mL) at -10 °C. The mixture was stirred at 25 °C for 40 minutes. After the reaction was complete, 1.00 M TEAB was added to adjust the pH to 7. The solution was diluted with H2O and extracted with MTBE. The aqueous phase was concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain ((2S,3S,4R,5R)-5-(4-amino-7H-Pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate (compound 75, 13.0 mg, 24.0 μmol, 10% yield) is a brown solid. ¹H NMR (400 MHz, D₂O) δ ppm 8.15 (s, 1H), 7.32 (d, J = 3.60 Hz, 1H), 6.67 (d, J = 4.0 Hz, 1H), 6.44 (d, J = 2.0 Hz, 1H), 4.80–4.78 (m, 1H), 4.39–4.29 (m, 3H). 31P NMR (162 MHz, D2O) δ ppm -10.4--10.1 (1P), -11.9--11.8 (1P), -22.9--22.7 (1P) LCMS (ESI): 522.9 [M-H]-.

[0210] Compounds 76-85 were synthesized using a procedure similar to that used for compound 75. Instruction manual, page 57 / 81, number 71 (CN 121358746 A); page 58 / 81, number 72 (CN 121358746 A); page 59 / 81, number 73 (CN 121358746 A); page 60 / 81, number 74 (CN 121358746 A); page 61 / 81, number 75 (CN 121358746 A); page 62 / 81, number 76 (CN 121358746 A); page 63 / 81, number 77 (CN 121358746 A); page 64 / 81, number 78 (CN 121358746 A); page 65 / 81, number 79 (CN 121358746 A); page 66 / 81, number 80 (CN 121358746 A); page 67 / 81, number 81 (CN 121358746 A). Instruction manual 68 / 81 pages 82 CN 121358746 A Instruction manual 69 / 81 pages 83 CN 121358746 A

[0211] Bioassay DENV-2 virus stock solution generation 5 E 6 Vero cells (ATCCCCL-8 1) were plated in complete DMEM containing 10% FBS, 1× NEAA (Thermofisher, 11140-050) 1× PenStrep (Thermofisher, 15140-122)In a T150 flask containing (Gibco, 11965-092), culture medium was incubated overnight at 37°C with 5% CO2. The medium was removed from the flask, and 10 mL of DENV-2 16681 (GenBank NC_001474.2) diluted in DMEM containing 2% FBS was added at an MOI of 0.01. The flask was then allowed to incubate at 37°C with 5% CO2 for one hour. After incubation, 15 mL of complete DMEM was added, and the flask was incubated at 33°C with 5% CO2 for 15 days. The supernatant was harvested every two to three days, and 25 mL of fresh medium was added to the flask. Specifically, the supernatant was harvested, centrifuged at 2,000 × g for 5 minutes at 4°C, aliquoted, and stored at -80°C.

[0212] Preparation of Zika virus stock solution: 5 E 6 Vero cells (ATCCCCL-81) were plated in a T150 flask containing 10% FBS, 1× NEAA (Thermofisher, 11140-050), and 1× PenStrep (Thermofisher, 15140-122) in complete DMEM (Gibco, 11965-092), and incubated overnight at 37°C and 5% CO2. The culture medium was removed from the flask, and 10 mL of ZIKV MR766 (BEI Resources NR-50065) diluted in DMEM containing 2% FBS was added to the flask at an MOI of 0.01, and incubated at 37°C and 5% CO2 for one hour. After incubation, 15 mL of complete DMEM was added, and the flask was incubated for 3 days in an incubator containing 5% CO2 at 37°C. The supernatant was then harvested and centrifuged at 2,000×g for 5 minutes at 4°C, then aliquoted and stored at -80°C.

[0213] Preparation of yellow fever virus stock solution: 5 E 6 Vero cells (ATCCCCL-8 1) were plated in a T150 flask containing complete DMEM (Gibco, 11965-092) containing 10% FBS, 1× NEAA (Thermofisher, 11140-050) and 1× PenStrep (Thermofisher, 15140-122), and incubated overnight at 37°C with 5% CO2. Remove the culture medium from the flask and add 10 mL of YFV strain 17D (BEI Resources NR-116) diluted in DMEM containing 2% FBS (page 70 / 81, CN 121358746 A, manual specification) at an MOI of 0.01. Allow the mixture to incubate at 37°C for 5% FBS.Incubate at CO2 for one hour. After incubation, add 15 mL of complete DMEM and incubate the flask at 37°C in an incubator containing 5% CO2 for 3 days. Then harvest the supernatant and centrifuge at 2,000×g for 5 minutes at 4°C, then divide into equal portions and store at -80°C.

[0214] Preparation of Chikungunya virus stock solution: 5 E 6 Vero cells (ATCCCCL-8 1) were plated in a T150 flask containing complete DMEM (Gibco, 11965-092) containing 10% FBS, 1× NEAA (Thermofisher, 11140-050) and 1× PenStrep (Thermofisher, 15140-122) and incubated overnight at 37°C in 5% CO2. Remove the culture medium from the flask and add 10 mL of CHIKV strain 181 / 25 (BEI Resources NR-56523) diluted in DMEM containing 2% FBS at an MOI of 0.005. Allow the flask to incubate at 37°C and 5% CO2 for one hour. After incubation, add 20 mL of complete DMEM to the flask and incubate at 37°C in a 5% CO2 incubator for 3 days. Then harvest the supernatant, centrifuge at 2,000×g for 5 minutes at 4°C, aliquot, and store at -80°C.

[0215] SARS-CoV-2 virus stock solution generation: Vero E6 cells (ATCC CRL-1586) were plated in T150 flasks containing 10% FBS, complete DMEM (Corning 15-013-CV), 1×PenStrep (Corning 20-002-CL), and 2 mM L-glutamine (Corning 25-005-CL), and incubated overnight at 37°C with 5% CO2. The culture medium was removed from the flasks, and 10 mL of SARS-CoV-2 strain USA-WA1 / 2020 (BEI Resources NR-52281) in complete DMEM was added to the flasks at an MOI of 0.05, and incubated at 34°C with 5% CO2 for 30 minutes. After incubation, 20 mL of complete DMEM was added to the flasks. The flasks were then placed in an incubator at 34°C with 5% CO2. On day 3 post-infection, cells were scraped from the supernatant, the mixture was harvested, and centrifuged at 2,000 × g for 5 minutes. The cell pellet was freeze-thawed three times, then resuspended in the collected supernatant, and centrifuged again at 2,000 × g for 5 minutes at 4°C. The pellet was then aliquoted and stored at -80°C.

[0216] HeLa-ACE2 stable cell lineHeLa-ACE2 cells were generated by transduction of human ACE2 lentivirus. Lentiviral virus was generated by co-transfecting HEK293T cells with the pBOB-hACE2 construct and lentiviral packaging plasmids pMDL, pREV, and pVSV-G (Addgene) using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019). The supernatant was collected 48 h after transfection and then used to transduce pre-inoculated HeLa cells. Stable cell lines were collected 12 h after transduction, expanded, and stored. Cells were maintained at 37°C and 5% CO2 in DMEM (Gibco, 11965-092) containing 10% FBS (Gibco, 10438026) and 1× sodium pyruvate (Gibco, 11360070).

[0217] Preparation of RSV virus.

[0218] To propagate RSV A2 (ATCC VR-1540), Hep-2 cells were infected at approximately 0.01 MOI for 1–2 hours in a humid 5% CO2 atmosphere at 37°C, with a confluence of 80–90%, and the inoculum was redistributed by shaking every 20–30 minutes. Afterward, the inoculum was removed and replaced with assay medium (DMEM containing 2% HI FBS, 1× Pen / Strep). The flasks were then incubated until significant CPE was typically observed 2–3 days post-infection. The supernatant was collected and clarified by centrifugation to remove cell debris. The virus was then stabilized by adding 25% sucrose and rapidly freezing aliquots, followed by storage at -80°C.

[0219] Preparation of seasonal coronaviruses HCoV-OC43 and HCoV-229E.

[0220] HCoV-OC43 was obtained from BEI Resources, NIAID, NIH: Human Coronavirus, OC43, NR-52725. To propagate the virus, HCT-8 cells were infected for two hours at 33°C and 5% CO2 in RPMI with an MOI of approximately 0.01. After incubation, the inoculum was removed and replaced with assay medium (RPMI containing 2% HI FBS, 1× Pen / Strep, and 2 mM L-glutamine). Flasks were incubated at 33°C and 5% CO2 until significant CPE was observed 3–4 days post-infection. Cells were scraped off and harvested along with the supernatant (see page 71 / 81 of the instruction manual, 85 CN 121358746 A), and centrifuged at 1,000×g for 5 minutes. The supernatant was collected, and the cell pellet was subjected to one freeze-thaw cycle, then resuspended in 5 mL of supernatant and re-clarified by centrifugation at 1,000×g for 5 minutes. The total supernatant was then collected, aliquoted, and stored at -80°C. HCoV-229E was obtained from BEI.Resources, NR52726. To propagate the virus, MRC-5 pd25 was infected with HCoV-229E in MEM at an MOI of approximately 0.01 and allowed to incubate at 37°C and 5% CO2 for two hours. After incubation, the inoculum was removed and replaced with assay medium (MEM supplemented with 10% HI FBS, 2 mM L-glutamine, 1% NEAA and 1×Pen / Strip). The flasks were then placed in an incubator at 37°C under 5% CO2 until significant CPE was observed 3–4 days post-infection, and harvested as described above for OC43.

[0221] Preparation of human rhinovirus stock solution.

[0222] Human rhinovirus strains 16 (ATCC VR-283), 14 (ATCC VR-284), and 1B (ATCC VR-1645) were propagated in H1 HeLa cells (ATCC CRL-1958). Cells were infected with the inoculum at 33°C and 5% CO2 in MEM at approximately 0.01 MOI for 2 hours. The inoculum was removed and replaced with assay medium (MEM + 2% FBS + 1 XPS), and the flasks were incubated for 2–3 days until significant CPE was observed. Cells were then scraped off and harvested along with the supernatant, and centrifuged at 1,000 × g for 5 minutes. The cell pellet was subjected to three freeze-thaw cycles, then resuspended in 5 mL of supernatant and clarified again by centrifugation. The total supernatant was then collected, aliquoted, and stored at -80°C.

[0223] Preparation of poliovirus stock solution.

[0224] Following a similar protocol to that used for HRV, attenuated poliovirus strains PV-1 CHAT (VR-1562) and PV-3 WM-3 (ATCC VR-300) were propagated in HeLa S3 cells (ATCC CCL-2.2).

[0225] The DENV-2 / HepG2 high-content screening antiviral assay was performed using an image-based method to evaluate the antiviral activity of the compounds against DENV-2 in HepG2 (ATCC HB-8065) ​​cells. The compounds were acoustically transferred to 384-well µm clear substrates (Greiner, part number 781090-2B) using an Echo 555 liquid processor (LabCyte Inc). Cells were seeded at a density of 2.0 × 10³ cells per well in 20 µL DMEM (HepG2) containing 2% FBS. Four hours later, 10 µL of inoculum (DENV-2 diluted in assay medium, MOI=0.5) was added to infect the plated cells to obtain ~50% infected cells. The plates were incubated at 37°C and 5% CO2 for 24 h, and then fixed with 4% formaldehyde at room temperature for 30 min. A period of time was observed between fixation and subsequent primary and secondary antibody staining.Wash the plate twice with 1xPBS 0.05% Tween 20. Add the anti-flavin envelope (E) protein [D1-4G2-4-15] antibody (Millipore) diluted 1:2000 in PBST-0.3% BSA-0.2% saponin to the plate and incubate overnight at 4°C. Add 1 µg / mL Alexa Fluor 488 goat anti-mouse IgG H+L: (Thermo Fisher Scientific A-11001) along with 8 µM of the anti-fluorescence quencher -46-diamidinyl-2-phenylindole (DAPI; Thermo Fisher Scientific D1306) diluted in PBST-0.3% BSA-0.2% saponin to each well and incubate at room temperature in the dark for 1 h. Image the plate using an ImageXpress miniature confocal high-content imaging system (Molecular Devices) with a 10× objective lens, imaging 4 fields of view per well. Images were analyzed using the MetaXpress multi-wavelength cell scoring application module. DAPI staining was used to confirm the host cell nuclei (total number of cells in the image), and DENV immunofluorescence signal was used to confirm infected cells.

[0226] The Zika virus / HepG2 high-content screening antiviral assay was performed using an image-based method. The antiviral activity of the compound against ZIKV was evaluated in HepG2 cells 24 hours after infection, following essentially the same protocol as described above for DENV-2, but using a dilution optimized to achieve ~50% ZIKV infection at 24 hours as the inoculum.

[0227] The yellow fever virus / HepG2 high-content screening antiviral assay was performed using an image-based method. The antiviral activity of the compound against YFV was evaluated in HepG2 cells 24 hours after infection, following essentially the same protocol as described above for DENV-2 and ZIKV, but using a dilution of yellow fever virus as the inoculum.

[0228] The Chikungunya / HepG2 high-content screening antiviral assay employed an image-based method and followed a protocol very similar to that described above for DENV-2, evaluating the antiviral activity of the compounds against Chikungunya in HepG2 at 24 hours post-infection, but with the following substitutions: a dilution of Chikungunya virus was used as the inoculum, and an anti-Chikungunya virus antibody was used as the primary antibody (CHIKV antibody 11E7, monoclonal mouse IgG2b, Kerafast).

[0229] The SARS-CoV-2 / HeLa-ACE2 high-content screening assay used an Echo 555 liquid processor (LabCyte Inc.) to acoustically transfer the compounds to 384-well µ-clear liquids.In a Greiner plate (part number 781090-2B), HeLa-ACE2 cells were seeded at a density of 1.0 × 10³ cells per well in 13 µL of DMEM containing 2% FBS. The plated cells were transferred to a BSL3 facility, where 13 µL of SARS-CoV-2 diluted in assay medium was added to obtain ~30–50% infected cells. The plates were incubated at 34 °C for 24 h at 5% CO2, and then fixed for 1 h at 34 °C for 5% CO2 with 4% formaldehyde. The plates were washed with 1xPBS 0.05% Tween 20 between fixation and subsequent primary and secondary antibody staining. Human polyclonal plasma diluted 1:500 in Perm / wash buffer (BD Biosciences 554723) was added to the plates and incubated at room temperature for 2 h. 6 µg / mL of goat anti-human H+L conjugated Alexa 488 (Thermo Fisher Scientific A11013) was added to the plate along with 8 µM of the antifluorescence quencher -46-diamidinyl-2-phenylindole (DAPI; Thermo Fisher Scientific D1306) in SuperBlock T20 (PBS) buffer (Thermo Fisher Scientific 37515), and the plate was incubated at room temperature in the dark for 1.5–2 hours. The plate was imaged using an ImageXpress miniature confocal high-content imaging system (Molecular Devices) with a 10× objective lens, with 4 fields of view per well. The images were analyzed using the MetaXpress multi-wavelength cell scoring application module. DAPI staining was used to confirm the host cell nuclei (total number of cells in the image), and SARS-CoV-2 immunofluorescence signal was used to confirm infected cells.

[0230] OC-43 / HCT-8 high-content screening assay.

[0231] The compound was acoustically transferred to a 384-well µ-clear substrate (Greiner, part number 781090-2B) using an Echo 555 liquid processor (LabCyte Inc). HCT-8 cells were seeded into assay preparation plates to reach 4000 cells in assay medium (RPMI-1640 + L-glutamine + 2% FBS + 1X penicillin / streptomycin solution). The plated cells were allowed to settle at 37°C for 1 hour, and then infected with HCoV-OC43 diluted in assay medium to obtain ~30-60% infected cells. The plates were incubated at 33°C and 5% CO2 for 48 h, and then fixed with formaldehyde to a final concentration of 4%. The fixed cells were blocked and treated with Superblock and 0.2%...Triton permeabilization was followed by overnight staining with mouse monoclonal antibody OC-43 strain clone 541-8F (Sigma Millipore MAB9012). This was followed by washing with PBS 0.05% Tween 20 between fixation and subsequent primary and secondary antibody staining with goat anti-mouse H+L conjugated Alexa 488 (Thermo Fisher Scientific A11001) and antifluorescence quencher -46-diamidine-2-phenylindole (DAPI; Thermo Fisher Scientific D1306). The plate was then imaged and analyzed as in the SARS-CoV-2 / HeLa-ACE2 assay.

[0232] Screening assay based on 229E / MRC5 CPE.

[0233] The compound was acoustically transferred to a 384-well µ transparent plate (Greiner, part number 781090-2B) using an Echo liquid processor in a dose-response manner (1:3 serial dilutions starting at a final maximum assay concentration of 10 µM). MRC-5 PD25 cells were seeded into assay preparation plates at a density of 500 cells per well. The plated cells were allowed to settle at 37°C for 1 hour, and then infected with hCoV-229E diluted in assay medium. The plates were incubated at 33°C and 5% CO2 for 120 h. To assess virus-induced cytopathic effect (CPE) by measuring cell viability, 20 μL of 50% Cell-Titer Glo (Promega No. G7573) diluted in water was added to the cells and luminescence was measured.

[0234] Screening assay based on HRV / H1 HeLa CPE.

[0235] The compound was acoustically transferred to 384-well or 1536-well µ transparent plates (Greiner, part number 781090-2B) in a dose-response manner using an Echo liquid processor. H1 HeLa cells were seeded into assay preparation plates at a density of 2000 cells per well in 384-well plates or 600 cells per well in 1536-well plates. The seeded cells were allowed to settle at 33°C for 4 hours, after which they were infected with HRV 16, 14, or 1B diluted in assay medium. The plates were incubated at 33°C with 5% CO2 for 48 hours. To assess virus-induced cytopathic effect (CPE) by measuring cell viability, 50% Cell-Titer Glo (Promega, G7573) diluted in water was added to the cells and luminescence was measured.

[0236] Screening assay based on PV / HeLa S3 CPE.

[0237] The compound was acoustically transferred to 384-well µ clear plates (Greiner, part number 781090-2B) using an Echo liquid processor in a dose-response manner. HeLa S3 cells were seeded into the assay preparation plate at a density of 4000 cells per well. The plated cells were allowed to settle at 37°C for 4 hours, after which they were infected with PV-1 CHAT or PV-3 WM-3 diluted in assay medium. The plates were incubated at 37°C for 48 hours in 5% CO2. To assess the virus-induced cytopathic effect (CPE) by measuring cell viability, 50% Cell-Titer Glo (Promega, part number G7573) diluted in water was added to the cells and luminescence was measured.

[0238] Screening assay based on RSV / Hep2 CPE.

[0239] The compound was acoustically transferred to 1536-well µ clear plates (Greiner, part number 781090-2B) using an Echo liquid processor in a dose-response manner. Hep2 cells were seeded into assay preparation plates at a density of 300 cells per well. The seeded cells were allowed to settle at 37°C for 1–2 hours, after which they were infected with RSV A2 diluted in assay medium. The plates were incubated for 72 hours. To assess virus-induced cytopathic effect (CPE) by measuring cell viability, 50% Cell-Titer Glo (Promega No. G7573) diluted in water was added to the cells and luminescence was measured.

[0240] Cytotoxicity counter screening of uninfected host cells quantified the ability of compounds to induce cytotoxicity in uninfected cells using a cell viability assay based on ATP measurements. Briefly, for both HepG2 and HeLa-ACE2 cells, the compounds were acoustically transferred to 1,536-well black substrate plates (Greiner, part number 789176-F) using an Echo 555 liquid processor (LabCyte Inc.). Cells were seeded at a density of 450 cells / well (HepG2) or 400 cells / well (Hela-ACE2) in 5 µL DMEM containing 2% FBS in assay preparation plates, and the plates were incubated at 37°C and 5% CO2 for 72 h (HepG2) or 24 h (Hela-ACE2). To assess cell viability, 2 µL of 50% Cell-Titer Glo (Promega number G7573) diluted in water was added to the cells, and luminescence was measured using a PheraStar or ClarioStar plate reader (BMG LabTech).

[0241] Data analysis and statistical methods were performed on DENV, ZIKV, YFV, CHIKV, SARS-CoV-2, HCoV-OC43, HCoV-229E, RSV, HRV, and PV infections.The results of the assays and the screening data for uninfected cytotoxicity counters were uploaded to Genedata Screener version 16.0. For high-content imaging assays, two outputs from image analysis were analyzed: % W2 or viral positivity as antiviral readings and total cell count. Data were normalized relative to neutral (DMSO) minus inhibitor controls (10 µM or 2.5 µM remdesivir for antiviral effects on DENV, SARS-CoV2, HCoV-OC43, and RSV, and 10 µM puromycin dihydrochloride for cytotoxicity in infected hosts). For screening for cytotoxicity counters in uninfected hosts, 30 µM puromycin dihydrochloride (Sigma) was used as a positive control. For HCoV-229E, RSV, HRV, and PV cell viability / CPE readings, data were normalized relative to stimulant controls (2.5 µM remdesivir for RSV and HCoV-229E, 1 µM AG-7404 for HRV) minus neutral controls (DMSO). For dose-response experiments, the compound specification page 74 / 81, 88 CN 121358746 A, was tested in triplicate, and the dose curve was fitted using the four-parameter Hill equation. The EC90 value was calculated from the EC50 and nHill values ​​exported from GeneData Screener in Excel according to the formula “POWER(9,1 / nHill)*EC50”.

[0242] Antiviral spectrum analysis performed by NIAID / Justin Julander All other antiviral assays were performed at Justin Julander / Justin Julander via the NIAID Preclinical Services platform. The following viral strains and cell lines were used:

[0243] The compounds were added to the cells before adding the virus at the appropriate MOI to induce visible CPE. When maximum CPE was observed in the viral control, the cells were stained with neutral red dye for dye uptake assays. These data were used to calculate the EC50, CC50, and selectivity index (SI=CC50 / EC50) for each compound. For compounds with SI.5, a virus reduction assay was performed, in which the supernatant collected from the CPE assay was titrated with virus. EC90 was calculated as the amount of compound required to reduce the virus titer by 1 log10.

[0244] The following data tables display bioassay data using the range codes shown below: Specification 75 / 81 pages 89 CN 121358746 A Specification 76 / 81 pages 90 CN 121358746 A Specification 77 / 81 pages 91 CN 121358746 A Specification 78 / 81 pages 92 CN121358746 A Specification 79 / 81 pages 93 CN 121358746 A Specification 80 / 81 pages 94 CN 121358746 A

[0245] For purposes of clarity and understanding, the foregoing disclosure has been described in detail to a certain extent by way of example and embodiments. It will be apparent to those skilled in the art that variations and modifications can be made within the scope of the claims. Therefore, it is to be understood that the foregoing description is intended to be illustrative rather than restrictive. Therefore, the scope of this disclosure should not be determined by reference to the foregoing description, but rather by reference to the claims and the full scope of the equivalent descriptions conferred by such claims.

[0246] This application references various granted patents, published patent applications, journal articles and other publications, each of which is incorporated herein by reference. Instruction manual, page 81 / 81, page 95, CN 121358746 A, Figure 1; Instruction manual, Figure 1 / 2, page 96, CN 121358746 A, Figure 2; Instruction manual, Figure 2 / 2, page 97, CN 121358746 A

Claims

1. A compound of Formula (I) wherein: R 1 selected from H, -C(=0)(Ci-C6)alkyl, -C(=0)(Ci-C6)heteroalkyl, -C(=0)(C3-C7)cycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)cycloalkyl, -C(=0)(C3-C7)heterocycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)heterocycloalkyl, -C(=0)(C6-Cio)aryl, -C(=0)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)(C5-C8)heteroaryl, -C(=0)(Ci-C6)alkyl(C5-C8)heteroaryl, -C(=0)CH(NH2)(Ci-C6)alkyl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl, -C(=0)CH(NH2)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl(C6-Cio)aryl, -P(=0)(OR 10 )2, -P(=0)(OR 10 )-P(=0)(OR 10 )2, -P(=0)(OR 10 )-P(=0)(OR 10 )2, -P(=0)(OR 1’ )NH(Ci-C6)alkyl, -P(=0)(OR 1’ )NH(Ci-C6)heteroalkyl, -P(=0)(OR 1’ )NH(Ci-C6)haloalkyl, -P(=0)(OR 1’ )NH(C3-C7)cycloalkyl, -P(=0)(OR 1’ )NH(C3-C7)heterocycloalkyl, -P(=0)(OR 1’ )NH(C6-Cio)aryl, -P(=0)(OR 1’ )NH(Ci-C6)alkyl(C6-Cio)aryl, -P(=0)(OR 1’ )NH(C5-C8)heteroaryl, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl, -P(=0)(NHR 1’ )NH(C1-C6)heteroalkyl, -P(=0)(NHR 1’ )NH(C1-C6)haloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)cycloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)heterocycloalkyl, -P(=0)(NHR 1’ )NH(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C6-C 10 )aryl, and -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C6-C 10 )aryl; Each R 1’ Independently, it is H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C 10 aryl, -(C1-C6)alkyl (C6-C 10 aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R 2a is H, halo, (Ci-C6)alkyl, or -CºCH; R 2b independently halo or OH; R 3 independently H or OH; R 4 is N3, halo, -CºN, (C1-C3)haloalkyl, or -O(C1-C6)alkyl; R 5 is H, halo, -C≡N, (C1-C6)alkyl, hetero(C1-C6)alkyl, hydroxy(C1-C6)alkyl, N(R 1’ )2, -C(=O)NH2; R 6 is H, halo, NH2, (Ci-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl; R 7 is H, NH2, OH, oxo, halo, N(R 1’ )2, or -O(C1-C6)alkyl; and R 8 is H or halo; with the proviso that the compound of Formula I is not 4-amino-7-((2R,3R,4S,5S)-5- fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3- d]pyrimidine-5-carboxamide; 4-amino-7-((2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5- carboxamide; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile; ((5-(4- amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran- 2-yl)methyl)triphosphonic acid; ((5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4- ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphonic acid; (5-(4-amino- 5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydro- furan-2-yl)methyl tetrahydrotriphosphonate; (5-(4-amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-4-ethynyl-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrotriphosphonate; 4-amino-7-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-4-ethynyl-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4- diol; including enantiomeric, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

2. A compound of Formula (II) wherein: R 1 Selected from H, -C(=O)(C1-C6)alkyl, -C(=O)(C1-C6)heteroalkyl, -C(=O)(C3-C7)cycloalkyl, -C(=O)(C1-C6)alkyl(C3-C7)cycloalkyl, -C(=O)(C3-C7)heteroalkyl, -C(=O)(C1-C6)alkyl(C3-C7)heteroalkyl, -C(=O)(C6-C 10 )aryl, -C(=O)(C1-C6)alkyl(C6-C 10 aryl, -C(=O)(C5-C8)heteroaryl, -C(=O)(C1-C6)alkyl(C5-C8)heteroaryl, -C(=O)CH(NH2)(C1-C6)alkyl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl, -C(=O)CH(NH2)(C1-C6)alkyl(C6-C 10 )aryl, -C(=O)CH(NH(C1-C6)alkyl)(C1-C6)alkyl(C6-C 10 )aryl, -C(=O)CH(N((C1-C6)alkyl)2)(C1-C6)alkyl(C6-C 10 )Aryl, -P(=O)(OR 1’ )2、-P(=O)(OR 1’ )-P(=O)(OR 1’ )2、-P(=O)(OR 1’ )-P(=O)(OR 1’ )-P(=O)(OR 1’ )2、-P(=O)(OR 1’ )NH(C1-C6)alkyl, -P(=O)(OR 1’ )NH(C1-C6) heteroalkyl, -P(=O)(OR 1’ )NH(C1-C6) haloalkyl, -P(=O)(OR 1’ )NH(C3-C7)cycloalkyl, -P(=O)(OR 1’ )NH(C3-C7) heterocyclic alkyl, -P(=O)(OR 1’ )NH(C6-C 10 )Aryl, -P(=O)(OR 1’ )NH(C1-C6)alkyl(C6-C 10 )Aryl, -P(=O)(OR 1’ )NH(C5-C8) heteroaryl, -P(=O)(OR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl, -P(=0)(NHR 1’ )NH(C1-C6)heteroalkyl, -P(=0)(NHR 1’ )NH(C1-C6)haloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)cycloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)heterocycloalkyl, -P(=0)(NHR 1’ )NH(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C6-C 10 )aryl, and -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C6-C 10 )aryl; Each R 1’ Independently, it is H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C 10 aryl, -(C1-C6)alkyl (C6-C 10 aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R 2 is H, (Ci-C6)alkyl or -CºCH; R 4 is N3, halo, or -O(Ci-C6)alkyl; R 5 is H, halo, -C≡N, hetero(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, N(R 1’ )2, -C(=O)NH2; R 6 is H, halo, NH2, (Ci-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl; R 7 is H, NH2, OH, halo, N(R 1’ )2, or -O(C1-C6)alkyl; and R 8 is H or halo; provided that the compound of Formula II is not (2S,3S,4R,5S)-5-(4-aminopyrrolo[2,1- f][1,2,4]triazin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3S,4R,5S)-5- (4-amino-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4- diol, (2R,3S,4R,5S)-5-(4-amino-5-fluoropyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5S)-5-(4-amino-pyrrolo[2,1-f][1,2,4]triazin-7- yl-5-fluoro-2-azido-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; ((2R,3S,4R,5S)-5-(4- aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrotriphosphate or ((((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-3,4- dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-D-alanine 2-ethylbutyl ester. d ) including enantiomeric, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

3. A compound of Formula (Ilia) or (Illb) wherein: R 1 H, -C(=0)(Ci-C6)alkyl, -C(=0)(Ci-C6)heteroalkyl, -C(=0)(C3-C7)cycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)cycloalkyl, -C(=0)(C3-C7)heterocycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)heterocycloalkyl, -C(=0)(C6-Cio)aryl, -C(=0)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)(C5-C8)heteroaryl, -C(=0)(Ci-C6)alkyl(C5-C8)heteroaryl, -C(=0)CH(NH2)(Ci-C6)alkyl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl, -C(=0)CH(NH2)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl(C6-Cio)aryl, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl, -P(=0)(NHR 1’ )NH(C1-C6)heteroalkyl, -P(=0)(NHR 1’ )NH(C1-C6)haloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)cycloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)heterocycloalkyl, -P(=0)(NHR 1’ )NH(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C6-C 10 )aryl, and -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C6-C 10 )aryl; Each R 1’ Independently, it is H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C 10 aryl, -(C1-C6)alkyl (C6-C 10 aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R 2a is H, OH, halo, (Ci-C6)alkyl, or -CºCH; R 2b is H, OH, halo, or (Ci-C6)alkyl; R 3a is H, OH, halo, or (Ci-C6)alkyl; R 3b is H, OH, halo, or (Ci-C6)alkyl; R 4 is N3, halo, -CºN, (C1-C3)haloalkyl, or -O(C1-C6)alkyl; R 6 and R 6’ each independently halo, NH2, NH(Ci-C6)alkyl, N((Ci-C6)alkyl)2, -OH, -0(Ci-C6)alkyl, -oxo, or -CºCH; and R 8 is H or halo; provided that the compound of Formula III is not (((2R,3S,4R,5R)-5-(2,6-diamino-9H-purin-9-yl)-2- (difluoromethyl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) triphosphate; (((2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-ethynyl-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl) triphosphate; (2S,3S,4R,5R)-5-(2,6-diamino-9H-purin-9-yl)-2-fluoro-2- (hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-4-ethynyl-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; including enantiomeric, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

4. A compound of Formula (IV) wherein: R 1 H, -C(=0)(Ci-C6)alkyl, -C(=0)(Ci-C6)heteroalkyl, -C(=0)(C3-C7)cycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)cycloalkyl, -C(=0)(C3-C7)heterocycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)heterocycloalkyl, -C(=0)(C6-Cio)aryl, -C(=0)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)(C5-C8)heteroaryl, -C(=0)(Ci-C6)alkyl(C5-C8)heteroaryl, -C(=0)CH(NH2)(Ci-C6)alkyl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl, -C(=0)CH(NH2)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl(C6-Cio)aryl, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 10 )2, -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl, -P(=0)(NHR 1’ )NH(C1-C6)heteroalkyl, -P(=0)(NHR 1’ )NH(C1-C6)haloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)cycloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)heterocycloalkyl, -P(=0)(NHR 1’ )NH(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C6-C 10 )aryl, and -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C6-C 10 )aryl; Each R 1’ Independently, it is H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C 10 aryl, -(C1-C6)alkyl (C6-C 10 aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R 4 is N3, halo, or -0(Ci-C6)alkyl; and R 6 is H, halo, (Ci-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl; including enantiomeric, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

5. A compound of Formula (V) wherein: R 1 H, -C(=0)(Ci-C6)alkyl, -C(=0)(Ci-C6)heteroalkyl, -C(=0)(C3-C7)cycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)cycloalkyl, -C(=0)(C3-C7)heterocycloalkyl, -C(=0)(Ci-C6)alkyl(C3-C7)heterocycloalkyl, -C(=0)(C6-Cio)aryl, -C(=0)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)(C5-C8)heteroaryl, -C(=0)(Ci-C6)alkyl(C5-C8)heteroaryl, -C(=0)CH(NH2)(Ci-C6)alkyl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl, -C(=0)CH(NH2)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(NH(Ci-C6)alkyl)(Ci-C6)alkyl(C6-Cio)aryl, -C(=0)CH(N((Ci-C6)alkyl)2)(Ci-C6)alkyl(C6-Cio)aryl, -P(=0)(OR 10 )2, -P(=0)(OR 10 )-P(=0)(OR 10 )2, -P(=0)(OR 10 )-P(=0)(OR 10 )2, -P(=0)(OR 1’ )NH(Ci-C6)alkyl, -P(=0)(OR 1’ )NH(Ci-C6)heteroalkyl, -P(=0)(OR 1’ )NH(Ci-C6)haloalkyl, -P(=0)(OR 1’ )NH(C3-C7)cycloalkyl, -P(=0)(OR 1’ )NH(C3-C7)heterocycloalkyl, -P(=0)(OR 1’ )NH(C6-Cio)aryl, -P(=0)(OR 1’ )NH(Ci-C6)alkyl(C6-Cio)aryl, -P(=0)(OR 1’ )NH(C5-C8)heteroaryl, -S(=0)(NR 1’ )2, -S(=0)(NR 1’ )2, -S(=0)(NR 1’ )2, -S(=0)(NR 1’ )2, -S(=0)(NR 10 )2, -S(=0)(NR 1’ )2, -S(=0)(NR 10 )2, -S(=0)(NR 1’ )2, -S(=0)(NR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl, -P(=0)(NHR 1’ )NH(C1-C6)heteroalkyl, -P(=0)(NHR 1’ )NH(C1-C6)haloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)cycloalkyl, -P(=0)(NHR 1’ )NH(C3-C7)heterocycloalkyl, -P(=0)(NHR 1’ )NH(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(NHR 1’ )NH(C5-C8)heteroaryl, -P(=0)(NHR 1’ )NH(C1-C6)alkyl(C5-C8)heteroaryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C1-C6)alkyl(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)alkyl-C(=0)0-(C6-C 10 )aryl, -P(=0)(OR 1’ )NH(C1-C6)heteroalkyl-C(=0)0-(C6-C 10 )aryl, and -P(=0)(OR 1’ )NH(C1-C6)haloalkyl-C(=0)0-(C6-C 10 )aryl; Each R 1’ Independently, it is H, -(C1-C6)alkyl, -(C1-C6)heteroalkyl, -(C1-C6)haloalkyl, -(C2-C6)alkenyl, -(C2-C6)heteroalkenyl, -(C2-C6)haloalkenyl, -(C2-C6)ynyl, -(C2-C6)heteroynyl, -(C2-C6)haloynyl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl, -(C6-C 10 aryl, -(C1-C6)alkyl (C6-C 10 aryl, -(C5-C8)heteroaryl or -(C1-C6)alkyl(C5-C8)heteroaryl; R 2 is H, halo, (Ci-C6)alkyl, or -CºCH; R 4 is N3, halo, -CºN, (C1-C3)haloalkyl, or -O(C1-C6)alkyl; R 5 is H, halo, -C≡N, hetero(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, halo(Ci-C6)alkyl, N(R 1’ )2, -(C(=O)NH2; R 6 is H, halo, NH2, (Ci-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl; R 7 is H, NH2, OH, halo, N(R 1’ )2, or -O(C1-C6)alkyl; and R 8 is H or halo; including enantiomeric, racemic and non-racemic mixtures, and further including pharmaceutically acceptable salts thereof.

6. The compound of claim 1, wherein R 2b is OH or halo.

7. The compound of claim 3, wherein R 2b is halo.

8. The compound of claim 7, wherein R 2a is Me or halo.

9. The compound of any one of claims 6-8, wherein R 2a is H.

10. The compound of any one of claims 6-8, wherein R 2a is (Ci-C6)alkyl.

11. The compound of claim 10, wherein R 2a is Me.​ 12. The compound of any one of claims 6-8, wherein R 2a is halo.

13. The compound of claim 12, wherein R 2a is Cl.​ 14. The compound of any one of claims 2 or 5, wherein R 2 is H.

15. The compound of any one of claims 2 or 5, wherein R 2 is halo.

16. The compound of claim 15, wherein R 2 is F.​ 17. The compound of any one of claims 2 or 5, wherein R 2 is (Ci-C6)alkyl.

18. The compound of claim 17, wherein R 2 is Me.​ 19. The compound of any one of claims 1-2 or 5, wherein R 5 is H.

20. The compound of any one of claims 1-2 or 5, wherein R 5 is -CH2OH.

21. The compound of any one of claims 1-2 or 5, wherein R 5 is -C(=0)NH2.

22. The compound of any one of claims 1, 6-13, or 19-21, wherein R 3 is OH.

23. The compound of any one of claims 1, 6-13, or 19-21, wherein R 3 is H.

24. The compound of any one of claims 1-23, wherein R 4 is halo.

25. The compound of claim 24, wherein R 4 is F.

26. The compound of claim 24, wherein R 4 is Cl.​ 27. The compound of any one of claims 1-23, wherein R 4 is N3.

28. The compound of any one of claims 1-23, wherein R 4 is -0(Ci-C6)alkyl.

29. The compound of claim 28, wherein R 4 is -OMe.​ 30. The compound of any one of claims 1-29, wherein R 6 is H or NH2, and R 6’ is -NH(Ci-C6)alkyl or -0(Ci-C6)alkyl.

31. The compound of any one of claims 1-29, wherein R 6 is halo.

32. The compound of claim 31, wherein R 6 is F.

33. The compound of any one of claims 1-29, wherein R 6 is -CºCH.

34. The compound of any one of claims 1-33, wherein R 1 is H.

35. The compound of any one of claims 1-33, wherein R 1 is -P(=0)(OR 1’ )2, -P(=0)(OR 1’ )-P(=0)(OR 1’ )2, or -P(=0)(OR 1’ )-P(=0)(OR 1’ )-P(=0)(OR 1’ )2.

36. The compound of any one of claims 1-33, wherein R 1 is -P(=0)(OR 1’ )NH(Ci-C6)alkyl-C(=0)0-(Ci-C6)alkyl.

37. A compound having a formula selected from any one of: (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2- (hydroxymethyl)-2-methoxy-4-methyltetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3R,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-chloro-2,4- difluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-azido-4-chloro- 4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-azido-5- (hydroxymethyl)tetrahydrofuran-3-ol; (2R,3S,4R,5S)-5-(4-amino-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-azido-2- (hydroxymethyl)-4-methyltetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-fluoro-5- (hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-fluoro-5- (hydroxymethyl)tetrahydrofuran-3-ol; (2S,3S,4R,5R)-2-fluoro-5-(4-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; 4-amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; (2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro- 2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; (2S,3S,4R,5R)-5-(4-amino-5-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)- 2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(6-amino-2-ethynyl-9H-purin-9-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5S)-5-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(fluoromethyl)- 2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 5-fluoro-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4- one; (2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)- 2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-Fluoro-2-(hydroxymethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-Fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide; (2S,3S,4R,5R)-5-(5-Bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 4-Amino-7-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile; (2S,3S,4R,5R)-5-(2-Amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-Fluoro-2-(hydroxymethyl)-5-(6-(methylthio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-Chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (1S,2S,3S,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-3-(hydroxymethyl)cyclopentane-1,2-diol; (2S,3S,4R,5R)-5-(6-Amino-2-fluoro-9H-purin-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrofuran-2-carbonitrile; (2S,3S,4R,5R)-5-(4-Amino-5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; Benzoic acid ((2S,3S,4R,5S)-5-(4-amino-5-carbamoylpyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; (2S,3S,4R,5R)-2-Fluoro-5-(5-fluoro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(5-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 7-((2R,3R,4S,5S)-5-Fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile; 7-((2R,3R,4S,5S)-5-Fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile; (2R,3R,5R)-5-Fluoro-5-(hydroxymethyl)-2-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3-ol; (2S,3S,4R,5R)-2-Fluoro-2-(hydroxymethyl)-5-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-Amino-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(6-Amino-2-chloro-9H-purin-9-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran-3,4-diol; 4-Amino-1-((2R,3R,4S,5S)-3-ethynyl-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; (2S,3S,4R,5R)-2-((Benzoyloxy)methyl)-5-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)-2-fluorotetrahydrofuran-3,4-diyl diacetate; Isobutyric acid ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl) methyl ester; (2S,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate); ((S)-(((2S,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((R)-(((2S,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; Benzoic acid ((2S,3S,4R,5R)-4-(benzoyloxy)-5-(4-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3-hydroxytetrahydrofuran-2-yl) methyl ester; (2R,3R,4S,5S)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-5-fluoro-3,4- dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile; (2S,3S,4R,5R)-5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-5-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2- (hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3R,5R)-5-(4-amino-5-(benzo[d]thiazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)- 2,4,4-trifluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; Benzoic acid ((2S,3S,4R,5R)-5-(2-amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2-fluoro-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester; (2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-chloro-2,4-difluoro-2- (hydroxymethyl)tetrahydrofuran-3-ol; ((R)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-chloro-2,4- difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((S)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-chloro-2,4- difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; (2S,3R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-2,4,4-trifluoro-2- (hydroxymethyl)tetrahydrofuran-3-ol; ((((2S,3R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-2,4,4-trifluoro-3- hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; 2-amino-9-((2R,3R,4R,5S)-3-chloro-5-fluoro-4-hydroxy-5-(hydroxymethyl)-3- methyltetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one; (2S,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2-fluoro-2- (hydroxymethyl)-4-methyltetrahydrofuran-3-ol; ((((2S,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2-fluoro-3- hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; ((((2S,3S,4R,5R)-5-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alanine neopentyl ester; (2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2,4-difluoro-2- (hydroxymethyl)tetrahydrofuran-3-ol; ((((2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-chloro-2,4-difluoro-3- hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; (2S,3R,4S,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-bromo-2,4-difluoro-2- (hydroxymethyl)tetrahydrofuran-3-ol; ((((2S,3R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-2,4,4-trifluoro-3-hydroxytetrahydrofuran- 2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine isopropyl ester; (2S,3S,4R,5R)-4-ethynyl-2-fluoro-2-(hydroxymethyl)-5-(4-(propylamino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; 2-amino-9-((2R,4R,5S)-3,3,5-trifluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 1,9-dihydro-6H-purin-6-one; (2S,3S,4R,5R)-2-fluoro-2-(hydroxymethyl)-5-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydrofuran-3,4-diol; L-valine ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl ester; ((((2S,3S,4R,5R)-5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alanine neopentyl ester; ((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate; ((2S,3S,4R,5R)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3S,4R,5R)-2-fluoro-3,4-dihydroxy-5-(4-oxo-3,4-dihydro-7H-pyrrolo[2,3- d]pyrimidin-7-yl)tetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3S,4R,5R)-5-(5-carbamoyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3S,4R,5R)-5-(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3S,4R,5R)-2-fluoro-5-(5-fluoro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3S,4R,5R)-5-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3S,4R,5R)-5-(4-amino-5-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3S,4R,5R)-5-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxytetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; ((2S,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-4-chloro-2-fluoro-3- hydroxy-4-methyltetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester; and ((2S,3S,4S,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-3,4- dihydroxy-4-methyltetrahydrofuran-2-yl)methyl tetrahydro pyrophosphoric acid ester.

38. The compound of claim 37 having the chemical formula (2S,3S,4R,5R)-5-(4- amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-fluoro-2-(hydroxymethyl)tetrahydrofuran- 3,4-diol or ((R)-(((2S,3R,4S,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4- chloro-2,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)- L-alanine isopropyl ester.

39. A pharmaceutical composition comprising a compound of any one of claims 1-38 in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.

40. The pharmaceutical composition of claim 39, further comprising one or more therapeutic compounds or compositions.

41. The pharmaceutical composition of claim 40, wherein the one or more therapeutic compounds or compositions is a second antiviral compound or composition.

42. The pharmaceutical composition of claim 41, wherein the second antiviral compound or composition is an RdRp inhibitor.

43. The pharmaceutical composition of claim 41, wherein the second antiviral compound or composition is an RNA polymerase inhibitor.

44. A method of inhibiting an RNA-dependent RNA polymerase comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-38 or a pharmaceutical composition of claims 39-43.

45. A method of preventing, ameliorating, or treating an RNA viral infection comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-38 or a pharmaceutical composition of claims 39-43.

46. The method of claim 45, wherein the RNA viral infection is at least one virus selected from the group consisting of dengue virus, severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-COV-2, Zika virus, yellow fever virus, Ebola (Makona) virus, Ebola (Kikwit) virus, O'nyong'nyong virus, Sudan virus, Marburg virus, respiratory syncytial virus (RSV), Nipah virus, measles virus, parainfluenza virus, Middle East respiratory syndrome (MERS) virus, hepatitis C virus (HCV), West Nile virus, Lassa virus, influenza, HRV, MEV, LCMV, polio, CHIKV, COXV, and Junin virus.

47. The method of claim 46, wherein the RNA viral infection is caused by dengue virus.

48. The method of claim 46, wherein the RNA viral infection is caused by SARS-COV-2 virus.

49. The method of claim 46, wherein the RNA viral infection is caused by yellow fever virus.

50. The method of claim 46, wherein the RNA viral infection is caused by Zika virus.

51. The method of any one of claims 44-50, further comprising treatment with one or more additional therapeutic compounds or compositions.

52. The method of claim 51, wherein at least one of the one or more therapeutic compounds or compositions is a drug effective to treat or ameliorate an RNA viral infection.

53. The method of claim 52, wherein the drug to treat an RNA viral infection is selected from remdesivir, monolupiravir, or paroquatreve.

54. Any compound, composition, or method described herein.